{"gene":"MYD88","run_date":"2026-06-10T05:19:52","timeline":{"discoveries":[{"year":1998,"finding":"MyD88 functions as an adaptor protein in IL-1 signaling: it forms homodimers via DD-DD and Toll-Toll interactions, co-immunoprecipitates with the IL-1R signaling complex in an IL-1-dependent manner, and overexpression activates JNK and NF-κB through its death domain. A point mutation (F56N/MyD88-lpr) that prevents DD dimerization blocks these activities. Dominant negative versions of TRAF6 and IRAK inhibit MyD88-induced NF-κB activation.","method":"Co-immunoprecipitation, overexpression/dominant-negative constructs, point mutagenesis, reporter assays in 293 cells","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — multiple orthogonal methods (Co-IP, mutagenesis, reporter assays) in a single focused study; foundational mechanism paper replicated by subsequent work","pmids":["9575168"],"is_preprint":false},{"year":1999,"finding":"MyD88 is essential for LPS (endotoxin) responses downstream of TLR4: MyD88 knockout mice lack LPS-induced shock, B-cell proliferation, and cytokine secretion by macrophages and fibroblasts. However, NF-κB and MAP kinase activation are not abolished in MyD88-KO cells, demonstrating a MyD88-independent pathway also emanates from TLR4.","method":"MyD88 knockout mouse model; LPS challenge; cytokine measurement; NF-κB/MAPK assays","journal":"Immunity","confidence":"High","confidence_rationale":"Tier 2 / Strong — clean genetic KO with multiple defined phenotypic readouts; independently replicated across many subsequent studies","pmids":["10435584"],"is_preprint":false},{"year":2001,"finding":"MyD88 is required for LPS-induced cytokine production from dendritic cells but not for LPS-induced functional DC maturation (upregulation of costimulatory molecules). Both pathways originate from the TLR4 intracytoplasmic region, as both were abolished in C3H/HeJ (TLR4 mutant) DCs. MyD88 is absolutely required for TLR9 (bacterial DNA)-induced DC maturation, demonstrating differential pathway requirements across TLRs.","method":"MyD88-deficient and TLR4-mutant mouse DCs; LPS and CpG stimulation; costimulatory molecule upregulation; APC activity assays; cytokine measurement","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic KO with multiple orthogonal phenotypic readouts; discriminates two downstream pathways of TLR4","pmids":["11313410"],"is_preprint":false},{"year":2001,"finding":"Taxol (paclitaxel) LPS-mimetic activity requires both TLR4 and MyD88 for TNF and NO production and NF-κB-driven gene expression. Macrophages from TLR4-null or MyD88-KO mice produced minimal TNF/NO upon Taxol. However, Taxol-induced MAPK activation and NF-κB nuclear translocation were preserved in MyD88-KO macrophages (with slight kinetic delay), indicating a TLR4-dependent/MyD88-independent pathway also exists for these signals.","method":"TLR4-deficient and MyD88-KO primary macrophages; dominant-negative MyD88 transfection; TNF/NO measurement; NF-κB reporter/luciferase assay; MAPK activation assay","journal":"European journal of immunology","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple genetic models (KO and dominant-negative) with several orthogonal readouts; discriminates MyD88-dependent and -independent outputs","pmids":["11500829"],"is_preprint":false},{"year":2001,"finding":"Peptidoglycan (PGN) and micrococci signal through TLR2 to induce IL-8 via a sequential pathway TLR2→MyD88→IRAK→TRAF6→NIK→IKK→NF-κB. Dominant-negative MyD88 completely blocked PGN/micrococcus-induced NF-κB activation and IL-8 gene expression, positioning MyD88 immediately downstream of TLR2.","method":"Dominant-negative expression constructs (MyD88, IRAK, NIK, IKK, TRAF6) in HEK293 cells expressing TLR2/CD14; NF-κB reporter assay; IL-8 gene expression","journal":"Infection and immunity","confidence":"High","confidence_rationale":"Tier 2 / Strong — epistasis established by systematic dominant-negative analysis of each pathway component; multiple components tested","pmids":["11254583"],"is_preprint":false},{"year":2006,"finding":"MyD88 mediates a post-transcriptional mechanism downstream of IFN-γ receptor signaling: IFN-γ stimulation induces physical association between IFN-γR1 and MyD88. MyD88 increases the mRNA half-life (not synthesis) of IFN-γ-induced TNF and IP-10 transcripts via activation of mixed-lineage kinase 3 and p38 MAPK, requiring an AU-rich element in the 3′ UTR.","method":"Co-immunoprecipitation of IFN-γR1 with MyD88; mRNA stability assay; MyD88-deficient cells; kinase inhibitors; RNA half-life measurement","journal":"Nature immunology","confidence":"High","confidence_rationale":"Tier 1-2 / Moderate — reciprocal Co-IP plus functional mRNA stability assays and genetic KO, single lab with multiple orthogonal methods","pmids":["16491077"],"is_preprint":false},{"year":2007,"finding":"MyD88-5 (a vertebrate MyD88 family member) is preferentially expressed in neurons, co-localizes with mitochondria and JNK3, and recruits JNK3 from cytosol to mitochondria. Co-immunoprecipitation confirmed MyD88-5 interacts with JNK3. Hippocampal neurons from MyD88-5-deficient mice are protected from oxygen-glucose deprivation-induced death, whereas MyD88-5-null macrophages respond normally to microbial products.","method":"MyD88-5/GFP BAC transgenic mice; co-immunoprecipitation of MyD88-5 with JNK3; mitochondrial co-fractionation; MyD88-5-KO neurons; oxygen-glucose deprivation assay","journal":"The Journal of experimental medicine","confidence":"High","confidence_rationale":"Tier 1-2 / Moderate — Co-IP, subcellular fractionation, transgenic/KO models with defined neuronal death phenotype; multiple orthogonal methods in one study","pmids":["17724133"],"is_preprint":false},{"year":2008,"finding":"MyD88 acts as a scaffold to couple PKCε to TLRs: LPS-induced PKCε phosphorylation at Ser-346 and Ser-368, 14-3-3β binding, and recruitment to TLR4 are all MyD88-dependent. MyD88 overexpression causes constitutive PKCε phosphorylation; acute MyD88 knockdown abolishes Ser-346 phosphorylation. PKCε phosphorylation at these sites is required for TLR4- and TLR2-induced NF-κB activation and IκB degradation.","method":"MyD88-KO mouse embryo fibroblasts and macrophages; MyD88 knockdown in 293 cells; MyD88 overexpression; PKCε phosphorylation assays; TLR4 co-immunoprecipitation; NF-κB reporter assay in PKCε-/- reconstituted cells","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple genetic and biochemical approaches (KO, KD, OE, Co-IP, functional reconstitution) converging on same mechanism","pmids":["18458086"],"is_preprint":false},{"year":2009,"finding":"MyD88 interacts with PI3K p85 subunit via a YXXM motif in its TIR domain, and this interaction negatively regulates TLR4 signaling. A YXXM→YXXA mutant MyD88 bound more strongly to p85, TLR4, and wild-type MyD88, yet was less active than wild-type, suggesting sustained MyD88/PI3K interaction at the TLR4 signaling platform limits downstream output. LPS-induced Akt phosphorylation was blunted in MyD88−/− macrophages.","method":"Co-immunoprecipitation of MyD88 variants with PI3K p85, TLR4, and wild-type MyD88; MyD88 TIR/DD domain deletion and YXXM point mutants; Akt phosphorylation in MyD88-KO macrophages","journal":"Journal of leukocyte biology","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — Co-IP with domain mutants and KO macrophages, single lab; mechanistic conclusion (negative regulation) is supported but indirect","pmids":["19289601"],"is_preprint":false},{"year":2009,"finding":"Protein kinase D1 (PKD1) is activated downstream of MyD88 and IRAK4/1 (but not TRAF6) in TLR signaling. PKD1 is required for MyD88-dependent TRAF6 ubiquitination, TAK1 activation, MAPK and transcription factor activation, and proinflammatory gene expression. PKD1 does not contribute to TRIF-dependent type I IFN responses.","method":"PKD1 knockdown in macrophages and DCs; TLR ligand stimulation; TRAF6 ubiquitination assay; TAK1, MAPK and NF-κB activation assays; cytokine/IFN measurement","journal":"Journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — epistasis established by RNAi knockdown with multiple downstream readouts; single lab but several orthogonal assays","pmids":["19414785"],"is_preprint":false},{"year":2009,"finding":"PYK2 interacts with MyD88 (requiring MyD88's death domain) in vitro and in macrophages; this interaction is increased upon LPS stimulation. PYK2-deficient macrophages show reduced IκB phosphorylation/degradation, decreased NF-κB activation, and reduced IL-1β expression in response to LPS, placing PYK2 as a co-regulator upstream of NF-κB via interaction with MyD88.","method":"Co-immunoprecipitation of PYK2 with MyD88 in vitro and in macrophages; PYK2-KO macrophages; LPS stimulation; IκB phosphorylation/degradation; NF-κB activation assay","journal":"Journal of leukocyte biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP with domain requirement plus KO functional assay; single lab, two orthogonal methods","pmids":["19955209"],"is_preprint":false},{"year":2010,"finding":"The L265P mutation in the MYD88 TIR domain is a gain-of-function oncogenic driver in ABC DLBCL. The MYD88 L265P mutant spontaneously assembles a protein complex containing IRAK1 and IRAK4, leading to constitutive IRAK4 kinase activity, IRAK1 phosphorylation, NF-κB activation, JAK kinase activation of STAT3, and secretion of IL-6, IL-10, and IFN-β. Wild-type MYD88 did not substitute for L265P in sustaining ABC DLBCL cell survival.","method":"RNA interference screening; RNA resequencing; co-immunoprecipitation of MYD88 L265P with IRAK1/4; kinase activity assays; IRAK1 phosphorylation; NF-κB/STAT3 signaling assays; cytokine secretion measurement; rescue experiments with WT vs. L265P MYD88","journal":"Nature","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — multiple orthogonal methods (Co-IP, kinase assay, RNAi, rescue) in one rigorous study; independently replicated by multiple subsequent labs","pmids":["21179087"],"is_preprint":false},{"year":2010,"finding":"Two naturally occurring human MYD88 death-domain variants, S34Y and R98C, show severely reduced NF-κB activation due to impaired MyD88 homo-oligomerization and reduced IRAK4 interaction. Structural modeling identifies Ser-34 and Arg-98 as key residues for Myddosome assembly (the DD complex of MyD88, IRAK4, and IRAK2/1). MyD88 TIR domain and IRAK4 kinase domain modulate DD homo-oligomerization. S34Y and R98C differentially impair signaling through IL-1R, TLR2, TLR4, TLR5, and TLR7, but not TLR9.","method":"In vitro cellular NF-κB activation assay; co-immunoprecipitation for homo-oligomerization and IRAK4 binding; structural modeling; receptor-specific signaling assays with TLR2/4/5/7/9 and IL-1R","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1-2 / Moderate — mutagenesis, Co-IP, structural modeling, and multiple receptor-specific functional assays in one study","pmids":["20966070"],"is_preprint":false},{"year":2010,"finding":"IRAK1 and IRAK4 directly phosphorylate Mal (MyD88 adaptor-like/TIRAP), promoting its ubiquitination and proteasomal degradation. MyD88 itself is not a substrate for either IRAK and does not undergo degradation. This process negatively regulates TLR2 and TLR4 signaling.","method":"In vitro kinase assay with IRAK1/4; co-expression and immunoprecipitation; kinase-inactive IRAK mutants; LPS-induced ubiquitination assay; IRAK1/4 inhibitor; IRAK1/4 knockdown","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — direct in vitro kinase assay with mutagenesis controls; negative result for MyD88 as substrate is itself mechanistically informative","pmids":["20400509"],"is_preprint":false},{"year":2012,"finding":"MYD88 L265P triggers IRAK-mediated NF-κB signaling and is a somatic gain-of-function mutation found in ~91% of Waldenström's macroglobulinemia/lymphoplasmacytic lymphoma patients. Inhibition of MYD88 signaling reduced IκBα and NF-κB p65 phosphorylation and NF-κB nuclear translocation in WM cells expressing MYD88 L265P.","method":"Whole-genome sequencing; Sanger sequencing validation; MYD88 signaling inhibition assay; IκBα/NF-κB phosphorylation and nuclear staining in WM cells","journal":"The New England journal of medicine","confidence":"High","confidence_rationale":"Tier 2 / Strong — genomic discovery plus functional inhibition experiment; replicated across multiple independent cohorts","pmids":["22931316"],"is_preprint":false},{"year":2012,"finding":"MYD88 mediates an NF-κB-independent pathway downstream of IL-1β in endothelial cells: ARNO directly binds MYD88, and IL-1β signals through MYD88→ARNO→ARF6 to disrupt endothelial barrier function and vascular stability. This pathway is distinct from the canonical NF-κB transcriptional pathway.","method":"Direct binding assay (ARNO–MYD88 interaction); human endothelial cell model; NF-κB-independent assay; ARF6/ARNO functional experiments; animal models of inflammatory arthritis","journal":"Nature","confidence":"High","confidence_rationale":"Tier 1-2 / Moderate — direct binding demonstrated, NF-κB independence established, functional animal model; single lab with multiple methods","pmids":["23143332"],"is_preprint":false},{"year":2012,"finding":"In keratinocytes, oncogenic RAS establishes an autocrine signaling loop through IL-1α→IL-1R→MyD88 that leads to IκBα phosphorylation and NF-κB activation, driving proinflammatory gene expression and impairing differentiation. MyD88 exerts a cell-intrinsic function in RAS-mediated transformation; MyD88-/- RAS-expressing keratinocytes form only a few small tumors in orthotopic grafts.","method":"MyD88-/- and IL-1R-/- mice; oncogenic RAS expression in keratinocytes; orthotopic graft model; pharmacological and genetic IL-1α/NF-κB blockade; proinflammatory gene expression analysis","journal":"The Journal of experimental medicine","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic and pharmacological epistasis with multiple orthogonal approaches; cell-intrinsic function demonstrated by in vivo grafting","pmids":["22908325"],"is_preprint":false},{"year":2017,"finding":"TRAF6 and Pellino1/2 E3 ligases redundantly generate K63-linked ubiquitin chains for MyD88-dependent IL-1 signaling. In TRAF6/Pellino1/Pellino2 triple-KO cells, IL-1-induced K63-Ub chains, ubiquitylation of IRAK1, IRAK4, and MyD88, and TAK1 activation are abolished. Pellino1-generated K63-Ub chains activate TAK1 complex with similar efficiency to TRAF6-generated chains in vitro.","method":"TRAF6/Pellino1/Pellino2 triple-KO cells; E3 ligase-inactive TRAF6 knockin mice; ubiquitination assays; TAK1 activation assay in vitro; cytokine measurement; osteoclast differentiation assay","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — triple genetic KO combined with in vitro reconstitution and knockin mice; multiple orthogonal methods rigorously establish redundancy","pmids":["28404732"],"is_preprint":false},{"year":2017,"finding":"MyD88 promotes myoblast fusion in a cell-autonomous manner. MyD88 protein levels increase during in vitro myogenesis and in conditions of skeletal muscle growth. Deletion of MyD88 impairs fusion without affecting myoblast survival, proliferation, or differentiation. MyD88 regulates non-canonical NF-κB and canonical Wnt signaling during myogenesis and promotes overload-induced myofiber hypertrophy.","method":"MyD88 conditional deletion in myoblasts; in vitro myogenesis assay; overexpression of MyD88 in exogenous myoblasts; muscle regeneration and overload hypertrophy in vivo mouse models; NF-κB and Wnt signaling assays","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 / Strong — conditional KO plus overexpression with multiple in vitro and in vivo readouts; identifies distinct signaling outputs (non-canonical NF-κB, Wnt)","pmids":["29158520"],"is_preprint":false},{"year":2018,"finding":"MyD88 L265P protein is present in extracellular vesicles (EVs) shed from WM cells and can be transferred into recipient mast cells and macrophages. Transferred MyD88 L265P recruits endogenous wild-type MyD88, triggering proinflammatory signaling in the absence of receptor activation. This transfer was also observed in vivo in mice and MyD88-loaded EVs were detected in bone marrow aspirates of WM patients.","method":"EV isolation and characterization; confocal microscopy of EV uptake; co-immunoprecipitation of MyD88 L265P with endogenous MyD88; signaling assays in recipient cells; in vivo mouse EV injection; patient bone marrow aspirate analysis","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal methods (Co-IP, imaging, functional signaling, in vivo) in one study demonstrating novel intercellular transfer mechanism","pmids":["29358175"],"is_preprint":false},{"year":2019,"finding":"BANK1 directly binds MyD88 (and TRAF6) via its TIR domain, as demonstrated by co-immunoprecipitation. The natural BANK1-40C variant shows increased binding to MyD88. BANK1 co-localizes with TLR7/9, TRAF6, and MyD88 in mouse splenic B cells and co-localization increases after TLR7/9 agonist stimulation.","method":"Co-immunoprecipitation of BANK1 with MyD88 and TRAF6; domain deletion and point mutation experiments; confocal co-localization in mouse splenic B cells; TLR7/9 agonist stimulation","journal":"Cellular & molecular immunology","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — Co-IP with domain mapping and co-localization; single lab with two orthogonal methods but limited functional reconstitution","pmids":["31243359"],"is_preprint":false},{"year":2020,"finding":"SPOP (a Cullin 3-based ubiquitin ligase adaptor) recognizes the intermediate domain of MyD88 and promotes its proteasomal degradation, negatively regulating NF-κB pathway activity. Knockdown or genetic ablation of SPOP leads to elevated MyD88 protein and increased IL-1β production upon LPS challenge in macrophages. Spop-deficient mice are more susceptible to Salmonella infection.","method":"Co-immunoprecipitation of SPOP with MyD88; domain mapping of MyD88 interaction; SPOP knockdown and KO; proteasome inhibitor experiments; NF-κB/IL-1β functional assays; Salmonella infection model","journal":"PLoS pathogens","confidence":"High","confidence_rationale":"Tier 2 / Moderate — Co-IP with domain mapping, genetic KO, proteasome pathway confirmed, and in vivo infection model; multiple orthogonal methods","pmids":["32365080"],"is_preprint":false},{"year":2020,"finding":"Mutated MYD88 L265P activates SYK (a BCR signaling component): p-SYK co-immunoprecipitates with MYD88 in MYD88-mutated lymphoma cells, and confocal microscopy confirms co-localization. MYD88 knockdown or signaling inhibition abrogates SYK activation, while expression of mutated (but not wild-type) MYD88 amplifies p-SYK. SYK supports p-STAT3 and p-AKT signaling in MYD88-mutated cells.","method":"Co-immunoprecipitation of p-SYK with MYD88; confocal co-localization; MYD88 knockdown; MYD88 signaling inhibitor; expression of mutant vs WT MYD88; SYK inhibitor/knockdown; cell viability assays","journal":"Blood cancer journal","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reciprocal Co-IP plus confocal co-localization and genetic/pharmacological perturbations; single lab, multiple methods","pmids":["32005797"],"is_preprint":false},{"year":2021,"finding":"E3 ligase RNF138 catalyzes K63-linked non-proteolytic polyubiquitination of MYD88 L265P (but not wild-type MYD88), which enhances IRAK recruitment and NF-κB activation. A20 mediates K48-linked ubiquitination of RNF138 for proteasomal degradation, acting as a counter-regulatory mechanism. Mutation of MYD88 L265P ubiquitination sites or RNF138 knockdown abolishes constitutive NF-κB activation.","method":"Ubiquitination assay distinguishing K63 vs K48 linkage; RNF138 knockdown; MYD88 L265P ubiquitination site mutagenesis; co-immunoprecipitation; NF-κB activity assays; lymphoma growth experiments","journal":"Blood","confidence":"High","confidence_rationale":"Tier 1-2 / Moderate — in vitro ubiquitination assays, site-directed mutagenesis, and functional NF-κB readouts; mutation-specific biochemical mechanism rigorously established","pmids":["33025009"],"is_preprint":false},{"year":2021,"finding":"Pathological tau (pTau) activates IL-1β via a MyD88- and NLRP3-ASC-dependent pathway in myeloid cells/microglia. Deletion of MyD88 prevents both IL-1β expression and activation in the hTau mouse model of tauopathy.","method":"MyD88 deletion in hTau mice; NLRP3/ASC/caspase-1 inhibition; inflammasome activation assays; IL-1β measurement; mouse behavioral/cognitive assessment","journal":"Cell reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic deletion with defined molecular and behavioral readouts; single lab; pathway placement established by epistasis","pmids":["34551296"],"is_preprint":false},{"year":2022,"finding":"The IRAK4 scaffold (independent of its kinase activity) is required for TRAF6 activation by both MYD88 and TRIF downstream of TLR4, integrating the two TLR4 signaling pathways. IRAK4 kinase activity is essential for MYD88-dependent signaling specifically.","method":"IRAK4 knockout and kinase-inactive/scaffold mutant reconstitution in TLR4-stimulated cells; TRAF6 activation assays; MYD88 and TRIF signaling readouts","journal":"Cell reports","confidence":"High","confidence_rationale":"Tier 2 / Moderate — genetic KO combined with reconstitution of scaffold vs kinase-inactive IRAK4 mutants; rigorously dissects scaffold vs enzymatic roles","pmids":["35977521"],"is_preprint":false},{"year":2022,"finding":"MYD88 in osteocytes directly drives bacterially-induced osteolysis via RANKL upregulation. Osteocyte-specific MYD88 deletion protects against PAMP-induced calvarial osteolysis and P. gingivalis-driven alveolar bone resorption. Mechanistically, osteocyte MYD88 activation increases CREB and STAT3 binding to RANKL enhancers and suppresses K48-ubiquitination of CREB/CBP and STAT3.","method":"Osteocyte-specific MYD88 KO and restoration mice; calvarial PAMP injection model; oral P. gingivalis infection model; RANKL expression assay; ChIP for CREB/STAT3 at Rankl enhancers; ubiquitination assay; systemic MYD88 inhibitor treatment","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 / Strong — cell-type-specific KO and restoration in vivo, ChIP, ubiquitination assays, and pharmacological inhibition; multiple orthogonal methods; replicated in two disease models","pmids":["36333322"],"is_preprint":false},{"year":2022,"finding":"MYD88 directly blocks autophagic degradation of STING1, causing subsequent IRF3/JUN-mediated ACOD1 (IRG1) gene transcription and itaconate production in myeloid cells following TLR4 signaling. CGAS (the DNA sensor) does not contribute to this STING1-dependent ACOD1 expression; MYD88 is the key adaptor. STING1 deletion in myeloid cells abolishes ACOD1/itaconate production.","method":"STING1 and MYD88 deletion/interaction studies; cyclic dinucleotide stimulation; autophagic degradation assay; ACOD1 expression and itaconate measurement; myeloid-specific STING1 KO mice; endotoxemia and sepsis models","journal":"iScience","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic KO, direct MYD88-STING1 interaction implied by functional epistasis, multiple readouts; single lab","pmids":["35769880"],"is_preprint":false},{"year":1997,"finding":"MyD88 has a modular gene structure with an N-terminal death domain (encoded by exon 1) and C-terminal TIR (Toll/IL-1 receptor) domain. It is an evolutionarily conserved, widely expressed gene mapped to mouse chromosome 9 distal region and human chromosome 3p22-p21.3.","method":"cDNA cloning; gene structure analysis (5 exons); interspecific backcross mapping; somatic cell hybrid mapping; Northern blot; RT-PCR","journal":"Genomics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct structural characterization by cloning and mapping with multiple analytical methods; foundational structural paper","pmids":["9344657"],"is_preprint":false},{"year":2016,"finding":"In adenovirus keratitis, MyD88 co-immunoprecipitates with Src kinase in infected mouse corneas and human corneal fibroblasts, and MyD88 inhibitory peptide reduces Src phosphorylation. TLR2 and TLR9 act synergistically; MyD88-/- mice show markedly reduced keratitis and inflammatory cytokine expression.","method":"Co-immunoprecipitation of MyD88 with Src kinase; MyD88 inhibitory peptide; MyD88-/-, TLR2-/-, TLR9-/-, and TLR2/9 double-KO mouse infection model; Src phosphorylation assay; cytokine expression","journal":"Immunology and cell biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP plus genetic KO and pharmacological inhibition; single lab with multiple genetic models","pmids":["27528076"],"is_preprint":false}],"current_model":"MyD88 is a cytoplasmic adaptor protein with an N-terminal death domain and C-terminal TIR domain that serves as the universal scaffold for nearly all TLR and IL-1R/IL-18R family signaling: upon receptor activation it homo-oligomerizes via DD-DD and TIR-TIR interactions, recruits IRAK4 and IRAK1/2 into the 'Myddosome' complex (assembly requiring specific DD residues), leading to TRAF6/Pellino-dependent K63-ubiquitin chain formation, TAK1 activation, and downstream NF-κB and MAPK activation; it also scaffolds PKCε and PYK2, couples IFN-γR1 to post-transcriptional mRNA stabilization via p38, and mediates a non-canonical MYD88→ARNO→ARF6 pathway for vascular permeability; the oncogenic L265P TIR-domain mutation causes spontaneous Myddosome assembly, constitutive IRAK4 kinase activation, NF-κB/STAT3/JAK signaling, and is selectively polyubiquitinated by RNF138 on K63 linkages to further amplify signaling; MyD88 abundance is controlled by SPOP-mediated proteasomal degradation and by transfer via extracellular vesicles between cells."},"narrative":{"mechanistic_narrative":"MYD88 is a cytoplasmic adaptor with an N-terminal death domain (DD) and C-terminal TIR domain that serves as the central signaling scaffold for the IL-1R and Toll-like receptor (TLR) families [PMID:9575168, PMID:9344657]. Upon ligand engagement it homodimerizes through DD-DD and TIR-TIR interactions, couples to the receptor, and activates JNK and NF-κB; mutations that block DD dimerization abolish this activity [PMID:9575168]. MYD88 nucleates assembly of the 'Myddosome', recruiting IRAK4 and IRAK1/2 via DD interactions that depend on specific residues such as Ser-34 and Arg-98 [PMID:20966070], whereupon IRAK4 kinase activity drives downstream signaling while the IRAK4 scaffold function integrates MYD88- and TRIF-dependent arms of TLR4 [PMID:35977521]. Signal propagation requires K63-linked polyubiquitin chains generated redundantly by TRAF6 and Pellino1/2, which ubiquitinate IRAK1, IRAK4 and MYD88 itself to activate TAK1 and downstream MAPK/NF-κB cascades [PMID:28404732], with PKD1 acting downstream of MYD88/IRAK to license TRAF6 ubiquitination [PMID:19414785]. Genetic studies established MYD88 as essential for responses to LPS via TLR4, peptidoglycan via TLR2, and CpG DNA via TLR9, while revealing parallel MYD88-independent TLR4 outputs [PMID:10435584, PMID:11313410, PMID:11254583]. Beyond canonical NF-κB signaling, MYD88 scaffolds PKCε and PYK2 to TLR4 [PMID:18458086, PMID:19955209], couples IFN-γR1 to p38-dependent post-transcriptional stabilization of TNF and IP-10 mRNAs [PMID:16491077], and drives a non-canonical IL-1β→MYD88→ARNO→ARF6 pathway controlling endothelial barrier function [PMID:23143332]. MYD88 abundance is restrained by SPOP/Cullin-3-mediated proteasomal degradation [PMID:32365080]. The recurrent TIR-domain L265P mutation is a gain-of-function oncogenic driver in ABC-DLBCL and Waldenström's macroglobulinemia: it spontaneously assembles IRAK1/IRAK4 complexes, producing constitutive IRAK4 kinase activity, NF-κB and JAK/STAT3 signaling, and SYK activation [PMID:21179087, PMID:22931316, PMID:32005797], is selectively K63-polyubiquitinated by RNF138 to amplify signaling [PMID:33025009], and can be transferred between cells via extracellular vesicles to recruit endogenous wild-type MYD88 [PMID:29358175]. MYD88 also functions in non-immune contexts including myoblast fusion via non-canonical NF-κB and Wnt signaling [PMID:29158520], RAS-driven keratinocyte transformation [PMID:22908325], osteocyte-driven osteolysis through RANKL [PMID:36333322], and tauopathy-associated inflammasome activation [PMID:34551296].","teleology":[{"year":1997,"claim":"Establishing the modular DD-TIR architecture of MYD88 provided the structural framework for understanding how it would later be shown to bridge receptors and downstream kinases.","evidence":"cDNA cloning, gene structure analysis, and chromosomal mapping","pmids":["9344657"],"confidence":"Medium","gaps":["Did not establish function of either domain","No interaction partners identified at this stage"]},{"year":1998,"claim":"Demonstrating that MYD88 homodimerizes via its death domain and activates NF-κB/JNK downstream of the IL-1R established it as an adaptor that transmits receptor signals to TRAF6 and IRAK.","evidence":"Co-IP, dominant-negative and point mutants, reporter assays in 293 cells","pmids":["9575168"],"confidence":"High","gaps":["Stoichiometry and ordered assembly of the complex not resolved","Did not address TLR signaling"]},{"year":1999,"claim":"Genetic knockout showed MYD88 is essential for LPS/TLR4-driven inflammation yet revealed a parallel MYD88-independent pathway, defining the bifurcation of TLR4 signaling.","evidence":"MyD88-knockout mice, LPS challenge, cytokine and NF-κB/MAPK assays","pmids":["10435584"],"confidence":"High","gaps":["Identity of the MYD88-independent adaptor not defined here","Did not map which TLRs strictly require MYD88"]},{"year":2001,"claim":"Comparative TLR studies positioned MYD88 immediately downstream of TLR2 in a defined NF-κB cascade and showed differential MYD88 requirements across TLR4, TLR9 and distinct DC outputs.","evidence":"Dominant-negative epistasis in HEK293/TLR2 cells and MyD88/TLR4-deficient DCs and macrophages","pmids":["11254583","11313410","11500829"],"confidence":"High","gaps":["Mechanism distinguishing MYD88-dependent and -independent DC maturation unresolved","Did not address receptor-proximal complex assembly"]},{"year":2006,"claim":"Discovery that MYD88 associates with IFN-γR1 and stabilizes cytokine mRNAs via p38 extended its role beyond canonical NF-κB transcription to post-transcriptional control.","evidence":"Reciprocal Co-IP, mRNA half-life assays, MyD88-deficient cells, kinase inhibitors","pmids":["16491077"],"confidence":"High","gaps":["Direct vs indirect IFN-γR1–MYD88 binding not resolved","Trans-acting AU-rich element-binding effectors not identified"]},{"year":2007,"claim":"Characterization of the neuron-enriched MYD88-5 family member at mitochondria with JNK3 showed MYD88-family proteins can act outside microbial immunity in neuronal death.","evidence":"BAC transgenic and KO mice, Co-IP with JNK3, mitochondrial fractionation, oxygen-glucose deprivation","pmids":["17724133"],"confidence":"High","gaps":["Relationship of MYD88-5 to canonical MYD88 signaling unclear","Mechanism of JNK3 mitochondrial recruitment not detailed"]},{"year":2008,"claim":"Showing MYD88 scaffolds PKCε phosphorylation and recruitment to TLR4 broadened the adaptor's role to organizing additional kinases required for NF-κB activation.","evidence":"MyD88 KO/KD/OE, PKCε phosphorylation assays, TLR4 Co-IP, reconstitution in PKCε-/- cells","pmids":["18458086"],"confidence":"High","gaps":["Whether PKCε binds MYD88 directly not established","Position of PKCε relative to the Myddosome unresolved"]},{"year":2009,"claim":"Identification of PI3K p85, PKD1 and PYK2 as MYD88-associated regulators refined the proximal signaling network, including a negative-regulatory MYD88/PI3K interaction.","evidence":"Co-IP with domain/motif mutants, RNAi knockdown, KO macrophages, TRAF6 ubiquitination and NF-κB readouts","pmids":["19289601","19414785","19955209"],"confidence":"Medium","gaps":["Indirect support for PI3K negative regulation","Direct vs scaffolded interactions not all resolved"]},{"year":2010,"claim":"Defining DD residues required for Myddosome assembly and showing that the L265P TIR mutation drives spontaneous IRAK1/4 assembly transformed MYD88 from a normal adaptor into a defined oncogenic driver.","evidence":"Structural modeling, mutagenesis, Co-IP, RNAi/rescue, kinase and NF-κB/STAT3 assays in ABC-DLBCL","pmids":["20966070","21179087","20400509"],"confidence":"High","gaps":["High-resolution structure of mutant Myddosome not provided","Why L265P specifically destabilizes the autoinhibited state unclear"]},{"year":2012,"claim":"Linking MYD88 L265P to Waldenström's macroglobulinemia and uncovering non-canonical (ARNO/ARF6 vascular, RAS-keratinocyte) functions expanded the disease and signaling scope of the adaptor.","evidence":"Whole-genome sequencing of WM, MYD88 inhibition in WM cells; direct ARNO binding assays; MyD88/IL-1R KO RAS keratinocyte grafts","pmids":["22931316","23143332","22908325"],"confidence":"High","gaps":["Structural basis of ARNO–MYD88 binding not resolved","How L265P selects NF-κB vs alternative outputs unclear"]},{"year":2017,"claim":"Triple-knockout and reconstitution work resolved that TRAF6 and Pellino1/2 redundantly build the K63-ubiquitin chains that ubiquitinate IRAK1/4 and MYD88 to activate TAK1.","evidence":"TRAF6/Pellino1/2 triple-KO cells, ligase-dead TRAF6 knockin mice, in vitro TAK1 activation","pmids":["28404732"],"confidence":"High","gaps":["Relative physiological contribution of each ligase across cell types unresolved","Chain architecture on MYD88 itself not detailed"]},{"year":2018,"claim":"Demonstrating cell-autonomous MYD88 control of myoblast fusion via non-canonical NF-κB and Wnt showed a developmental role distinct from immune signaling.","evidence":"Conditional KO and overexpression, in vitro myogenesis, overload hypertrophy models","pmids":["29158520"],"confidence":"High","gaps":["Upstream receptor driving myogenic MYD88 unknown","Direct effectors linking MYD88 to Wnt unidentified"]},{"year":2019,"claim":"Showing that L265P MYD88 packaged in extracellular vesicles can transfer between cells and recruit endogenous wild-type MYD88 revealed a receptor-independent, intercellular mode of oncogenic signaling.","evidence":"EV isolation, confocal uptake, Co-IP, in vivo injection, patient bone marrow analysis","pmids":["29358175"],"confidence":"High","gaps":["Efficiency and physiological extent of transfer unclear","Whether recipient signaling sustains transformation not shown"]},{"year":2020,"claim":"Identifying SPOP-mediated degradation, BANK1 binding, and L265P-driven SYK activation defined both turnover control of MYD88 and additional partners shaping pathway output.","evidence":"Co-IP with domain mapping, SPOP KO/proteasome inhibition with Salmonella model; BANK1 Co-IP/co-localization; p-SYK Co-IP and perturbation in mutant lymphoma","pmids":["32365080","31243359","32005797"],"confidence":"Medium","gaps":["Direct vs indirect MYD88–SYK association unresolved","Functional consequence of BANK1–MYD88 binding limited"]},{"year":2021,"claim":"Discovery of RNF138-catalyzed mutation-specific K63-ubiquitination, with A20 counter-regulation, and a MYD88/NLRP3 axis in tauopathy refined mechanisms amplifying or extending MYD88 signaling.","evidence":"Linkage-specific ubiquitination assays, RNF138 knockdown and site mutagenesis, NF-κB readouts; MyD88 deletion in hTau mice","pmids":["33025009","34551296"],"confidence":"High","gaps":["Why RNF138 selects mutant over wild-type MYD88 not fully explained","Whether MYD88 acts upstream of inflammasome assembly directly unclear"]},{"year":2022,"claim":"Dissecting IRAK4 scaffold vs kinase roles, osteocyte MYD88-driven RANKL/osteolysis, and a MYD88→STING1→ACOD1 itaconate axis revealed how MYD88 integrates distinct downstream programs in different cell types.","evidence":"IRAK4 scaffold/kinase-dead reconstitution; osteocyte-specific KO/restoration with ChIP and ubiquitination assays; STING1/MYD88 deletion and itaconate measurement","pmids":["35977521","36333322","35769880"],"confidence":"High","gaps":["Direct MYD88–STING1 interaction not biochemically confirmed","How MYD88 selects transcriptional vs metabolic outputs unresolved"]},{"year":null,"claim":"How the wild-type vs L265P Myddosome achieves distinct conformational states and selects among the diverse downstream programs (NF-κB, STAT3, Wnt, ARF6, mRNA stabilization, itaconate) in a cell-type-specific manner remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No high-resolution structure of the mutant Myddosome","Rules governing output selection across cell types undefined","Quantitative contribution of vesicular MYD88 transfer in vivo unknown"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0060090","term_label":"molecular adaptor activity","supporting_discovery_ids":[0,7,12,25]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[5,8,15]}],"localization":[{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[0,7,11]},{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[7,8]},{"term_id":"GO:0005739","term_label":"mitochondrion","supporting_discovery_ids":[6]}],"pathway":[{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[0,1,2,4,11,17]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[0,5,15]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[11,14,19,23]},{"term_id":"R-HSA-392499","term_label":"Metabolism of proteins","supporting_discovery_ids":[17,21,23]}],"complexes":["Myddosome"],"partners":["IRAK4","IRAK1","TRAF6","IFNGR1","PRKCE","PTK2B","SPOP","RNF138"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q99836","full_name":"Myeloid differentiation primary response protein MyD88","aliases":[],"length_aa":296,"mass_kda":33.2,"function":"Adapter protein involved in the Toll-like receptor and IL-1 receptor signaling pathway in the innate immune response (PubMed:15361868, PubMed:18292575, PubMed:33718825, PubMed:37971847). Acts via IRAK1, IRAK2, IRF7 and TRAF6, leading to NF-kappa-B activation, cytokine secretion and the inflammatory response (PubMed:15361868, PubMed:19506249, PubMed:24316379, PubMed:40638072). Increases IL-8 transcription (PubMed:9013863). Involved in IL-18-mediated signaling pathway. Activates IRF1 resulting in its rapid migration into the nucleus to mediate an efficient induction of IFN-beta, NOS2/INOS, and IL12A genes. Upon TLR8 activation by GU-rich single-stranded RNA (GU-rich RNA) derived from viruses such as SARS-CoV-2, SARS-CoV and HIV-1, induces IL1B release through NLRP3 inflammasome activation (PubMed:33718825). MyD88-mediated signaling in intestinal epithelial cells is crucial for maintenance of gut homeostasis and controls the expression of the antimicrobial lectin REG3G in the small intestine (By similarity)","subcellular_location":"Cytoplasm; Nucleus","url":"https://www.uniprot.org/uniprotkb/Q99836/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/MYD88","classification":"Not Classified","n_dependent_lines":19,"n_total_lines":1208,"dependency_fraction":0.015728476821192054},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/MYD88","total_profiled":1310},"omim":[{"mim_id":"621051","title":"PARALEMMIN 3; PALM3","url":"https://www.omim.org/entry/621051"},{"mim_id":"620165","title":"LEUCINE-RICH REPEATS- AND CALPONIN HOMOLOGY DOMAIN-CONTAINING PROTEIN 4; LRCH4","url":"https://www.omim.org/entry/620165"},{"mim_id":"619990","title":"TRANSMEMBRANE p24 TRAFFICKING PROTEIN 7; TMED7","url":"https://www.omim.org/entry/619990"},{"mim_id":"619181","title":"FAMILY WITH SEQUENCE SIMILARITY 177, MEMBER A1; FAM177A1","url":"https://www.omim.org/entry/619181"},{"mim_id":"619070","title":"LETM1 DOMAIN-CONTAINING PROTEIN 1; LETMD1","url":"https://www.omim.org/entry/619070"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Cytosol","reliability":"Supported"},{"location":"Vesicles","reliability":"Additional"},{"location":"Mitochondria","reliability":"Additional"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in many","driving_tissues":[],"url":"https://www.proteinatlas.org/search/MYD88"},"hgnc":{"alias_symbol":[],"prev_symbol":[]},"alphafold":{"accession":"Q99836","domains":[{"cath_id":"1.10.533.10","chopping":"23-123","consensus_level":"high","plddt":87.1723,"start":23,"end":123},{"cath_id":"3.40.50.10140","chopping":"162-295","consensus_level":"high","plddt":85.1465,"start":162,"end":295}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q99836","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q99836-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q99836-F1-predicted_aligned_error_v6.png","plddt_mean":80.56},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=MYD88","jax_strain_url":"https://www.jax.org/strain/search?query=MYD88"},"sequence":{"accession":"Q99836","fasta_url":"https://rest.uniprot.org/uniprotkb/Q99836.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q99836/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q99836"}},"corpus_meta":[{"pmid":"10435584","id":"PMC_10435584","title":"Unresponsiveness of MyD88-deficient mice to endotoxin.","date":"1999","source":"Immunity","url":"https://pubmed.ncbi.nlm.nih.gov/10435584","citation_count":1574,"is_preprint":false},{"pmid":"21179087","id":"PMC_21179087","title":"Oncogenically active MYD88 mutations in human lymphoma.","date":"2010","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/21179087","citation_count":1221,"is_preprint":false},{"pmid":"22931316","id":"PMC_22931316","title":"MYD88 L265P somatic mutation in Waldenström's macroglobulinemia.","date":"2012","source":"The New England journal of medicine","url":"https://pubmed.ncbi.nlm.nih.gov/22931316","citation_count":978,"is_preprint":false},{"pmid":"25580251","id":"PMC_25580251","title":"MyD88: a central player in innate immune signaling.","date":"2014","source":"F1000prime reports","url":"https://pubmed.ncbi.nlm.nih.gov/25580251","citation_count":560,"is_preprint":false},{"pmid":"9575168","id":"PMC_9575168","title":"MyD88, an adapter protein involved in interleukin-1 signaling.","date":"1998","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9575168","citation_count":500,"is_preprint":false},{"pmid":"11313410","id":"PMC_11313410","title":"Endotoxin-induced maturation of MyD88-deficient dendritic cells.","date":"2001","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/11313410","citation_count":371,"is_preprint":false},{"pmid":"12217523","id":"PMC_12217523","title":"A universal role for MyD88 in TLR/IL-1R-mediated signaling.","date":"2002","source":"Trends in biochemical sciences","url":"https://pubmed.ncbi.nlm.nih.gov/12217523","citation_count":335,"is_preprint":false},{"pmid":"21057262","id":"PMC_21057262","title":"Clinical features and outcome of patients with IRAK-4 and MyD88 deficiency.","date":"2010","source":"Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/21057262","citation_count":319,"is_preprint":false},{"pmid":"19289601","id":"PMC_19289601","title":"TLR4/MyD88/PI3K interactions regulate TLR4 signaling.","date":"2009","source":"Journal of leukocyte biology","url":"https://pubmed.ncbi.nlm.nih.gov/19289601","citation_count":277,"is_preprint":false},{"pmid":"17202381","id":"PMC_17202381","title":"MyD88-dependent and MyD88-independent pathways in synergy, priming, and tolerance between TLR agonists.","date":"2007","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/17202381","citation_count":266,"is_preprint":false},{"pmid":"11500829","id":"PMC_11500829","title":"The role of MyD88 and TLR4 in the LPS-mimetic activity of Taxol.","date":"2001","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/11500829","citation_count":224,"is_preprint":false},{"pmid":"17724133","id":"PMC_17724133","title":"MyD88-5 links mitochondria, microtubules, and JNK3 in neurons and regulates neuronal survival.","date":"2007","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/17724133","citation_count":191,"is_preprint":false},{"pmid":"23532735","id":"PMC_23532735","title":"MYD88 L265P mutation in Waldenstrom macroglobulinemia.","date":"2013","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/23532735","citation_count":188,"is_preprint":false},{"pmid":"16491077","id":"PMC_16491077","title":"MyD88-mediated stabilization of interferon-gamma-induced cytokine and chemokine mRNA.","date":"2006","source":"Nature immunology","url":"https://pubmed.ncbi.nlm.nih.gov/16491077","citation_count":180,"is_preprint":false},{"pmid":"25132836","id":"PMC_25132836","title":"Toll-Like Receptors and Cancer: MYD88 Mutation and Inflammation.","date":"2014","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/25132836","citation_count":144,"is_preprint":false},{"pmid":"11254583","id":"PMC_11254583","title":"Micrococci and peptidoglycan activate TLR2-->MyD88-->IRAK-->TRAF-->NIK-->IKK-->NF-kappaB signal transduction pathway that induces transcription of interleukin-8.","date":"2001","source":"Infection and immunity","url":"https://pubmed.ncbi.nlm.nih.gov/11254583","citation_count":140,"is_preprint":false},{"pmid":"23143332","id":"PMC_23143332","title":"Interleukin receptor activates a MYD88-ARNO-ARF6 cascade to disrupt vascular stability.","date":"2012","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/23143332","citation_count":140,"is_preprint":false},{"pmid":"23255009","id":"PMC_23255009","title":"Experimental and natural infections in MyD88- and IRAK-4-deficient mice and humans.","date":"2012","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/23255009","citation_count":139,"is_preprint":false},{"pmid":"27869651","id":"PMC_27869651","title":"Pericyte MyD88 and IRAK4 control inflammatory and fibrotic responses to tissue injury.","date":"2016","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/27869651","citation_count":123,"is_preprint":false},{"pmid":"32931267","id":"PMC_32931267","title":"Myeloid Differentiation Primary Response Protein 88 (MyD88): The Central Hub of TLR/IL-1R Signaling.","date":"2020","source":"Journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/32931267","citation_count":110,"is_preprint":false},{"pmid":"25362351","id":"PMC_25362351","title":"A cell-intrinsic role for TLR2-MYD88 in intestinal and breast epithelia and oncogenesis.","date":"2014","source":"Nature cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/25362351","citation_count":103,"is_preprint":false},{"pmid":"20306472","id":"PMC_20306472","title":"SARM inhibits both TRIF- and MyD88-mediated AP-1 activation.","date":"2010","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/20306472","citation_count":103,"is_preprint":false},{"pmid":"15714580","id":"PMC_15714580","title":"MyD88 and TLR2, but not TLR4, are required for host defense against Cryptococcus neoformans.","date":"2005","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/15714580","citation_count":102,"is_preprint":false},{"pmid":"29703722","id":"PMC_29703722","title":"MYD88 L265P Mutation in Lymphoid Malignancies.","date":"2018","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/29703722","citation_count":99,"is_preprint":false},{"pmid":"33834387","id":"PMC_33834387","title":"MyD88 and beyond: a perspective on MyD88-targeted therapeutic approach for modulation of host immunity.","date":"2021","source":"Immunologic research","url":"https://pubmed.ncbi.nlm.nih.gov/33834387","citation_count":99,"is_preprint":false},{"pmid":"28404732","id":"PMC_28404732","title":"Roles of the TRAF6 and Pellino E3 ligases in MyD88 and RANKL signaling.","date":"2017","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/28404732","citation_count":96,"is_preprint":false},{"pmid":"19422846","id":"PMC_19422846","title":"Identification and characterization of TLR8 and MyD88 homologs in Atlantic salmon (Salmo salar).","date":"2009","source":"Developmental and comparative immunology","url":"https://pubmed.ncbi.nlm.nih.gov/19422846","citation_count":95,"is_preprint":false},{"pmid":"18308927","id":"PMC_18308927","title":"T cell expression of MyD88 is required for resistance to Toxoplasma gondii.","date":"2008","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/18308927","citation_count":93,"is_preprint":false},{"pmid":"22908325","id":"PMC_22908325","title":"IL-1R-MyD88 signaling in keratinocyte transformation and carcinogenesis.","date":"2012","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/22908325","citation_count":92,"is_preprint":false},{"pmid":"18390738","id":"PMC_18390738","title":"Uropathogenic Escherichia coli block MyD88-dependent and activate MyD88-independent signaling pathways in rat testicular cells.","date":"2008","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/18390738","citation_count":90,"is_preprint":false},{"pmid":"35977521","id":"PMC_35977521","title":"The IRAK4 scaffold integrates TLR4-driven TRIF and MYD88 signaling pathways.","date":"2022","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/35977521","citation_count":85,"is_preprint":false},{"pmid":"34551296","id":"PMC_34551296","title":"Proteopathic tau primes and activates interleukin-1β via myeloid-cell-specific MyD88- and NLRP3-ASC-inflammasome pathway.","date":"2021","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/34551296","citation_count":76,"is_preprint":false},{"pmid":"34371036","id":"PMC_34371036","title":"MyD88: At the heart of inflammatory signaling and cardiovascular disease.","date":"2021","source":"Journal of molecular and cellular cardiology","url":"https://pubmed.ncbi.nlm.nih.gov/34371036","citation_count":74,"is_preprint":false},{"pmid":"23660392","id":"PMC_23660392","title":"MyD88 and its divergent toll in carcinogenesis.","date":"2013","source":"Trends in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/23660392","citation_count":73,"is_preprint":false},{"pmid":"36180407","id":"PMC_36180407","title":"Schisandrin B Attenuates Diabetic Cardiomyopathy by Targeting MyD88 and Inhibiting MyD88-Dependent Inflammation.","date":"2022","source":"Advanced science (Weinheim, Baden-Wurttemberg, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/36180407","citation_count":68,"is_preprint":false},{"pmid":"25160558","id":"PMC_25160558","title":"MYD88 L265P mutation contributes to the diagnosis of Bing Neel syndrome.","date":"2014","source":"British journal of haematology","url":"https://pubmed.ncbi.nlm.nih.gov/25160558","citation_count":64,"is_preprint":false},{"pmid":"14638995","id":"PMC_14638995","title":"Mycobacterial infection in MyD88-deficient mice.","date":"2003","source":"Microbiology and immunology","url":"https://pubmed.ncbi.nlm.nih.gov/14638995","citation_count":63,"is_preprint":false},{"pmid":"23380077","id":"PMC_23380077","title":"MYD88 expression and L265P mutation in diffuse large B-cell lymphoma.","date":"2013","source":"Human pathology","url":"https://pubmed.ncbi.nlm.nih.gov/23380077","citation_count":60,"is_preprint":false},{"pmid":"12691620","id":"PMC_12691620","title":"Mal and MyD88: adapter proteins involved in signal transduction by Toll-like receptors.","date":"2003","source":"Journal of endotoxin research","url":"https://pubmed.ncbi.nlm.nih.gov/12691620","citation_count":60,"is_preprint":false},{"pmid":"29658361","id":"PMC_29658361","title":"MyD88 as a therapeutic target for inflammatory lung diseases.","date":"2018","source":"Expert opinion on therapeutic targets","url":"https://pubmed.ncbi.nlm.nih.gov/29658361","citation_count":59,"is_preprint":false},{"pmid":"15905587","id":"PMC_15905587","title":"Cross talk between MyD88 and focal adhesion kinase pathways.","date":"2005","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/15905587","citation_count":56,"is_preprint":false},{"pmid":"36333322","id":"PMC_36333322","title":"Osteocytes directly regulate osteolysis via MYD88 signaling in bacterial bone infection.","date":"2022","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/36333322","citation_count":55,"is_preprint":false},{"pmid":"20966070","id":"PMC_20966070","title":"Two human MYD88 variants, S34Y and R98C, interfere with MyD88-IRAK4-myddosome assembly.","date":"2010","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/20966070","citation_count":55,"is_preprint":false},{"pmid":"29158520","id":"PMC_29158520","title":"MyD88 promotes myoblast fusion in a cell-autonomous manner.","date":"2017","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/29158520","citation_count":54,"is_preprint":false},{"pmid":"20400509","id":"PMC_20400509","title":"IRAK1 and IRAK4 promote phosphorylation, ubiquitination, and degradation of MyD88 adaptor-like (Mal).","date":"2010","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/20400509","citation_count":52,"is_preprint":false},{"pmid":"19414785","id":"PMC_19414785","title":"Protein kinase D1 is essential for MyD88-dependent TLR signaling pathway.","date":"2009","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/19414785","citation_count":51,"is_preprint":false},{"pmid":"19019456","id":"PMC_19019456","title":"Differential induction of MyD88- and TRIF-dependent pathways in equine monocytes by Toll-like receptor agonists.","date":"2008","source":"Veterinary immunology and immunopathology","url":"https://pubmed.ncbi.nlm.nih.gov/19019456","citation_count":51,"is_preprint":false},{"pmid":"30086464","id":"PMC_30086464","title":"Dual functional roles of the MyD88 signaling in colorectal cancer development.","date":"2018","source":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","url":"https://pubmed.ncbi.nlm.nih.gov/30086464","citation_count":50,"is_preprint":false},{"pmid":"23983209","id":"PMC_23983209","title":"Mal, more than a bridge to MyD88.","date":"2013","source":"IUBMB life","url":"https://pubmed.ncbi.nlm.nih.gov/23983209","citation_count":50,"is_preprint":false},{"pmid":"23941302","id":"PMC_23941302","title":"Penta-O-galloyl-β-D-glucose ameliorates inflammation by inhibiting MyD88/NF-κB and MyD88/MAPK signalling pathways.","date":"2013","source":"British journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/23941302","citation_count":50,"is_preprint":false},{"pmid":"31243359","id":"PMC_31243359","title":"BANK1 interacts with TRAF6 and MyD88 in innate immune signaling in B cells.","date":"2019","source":"Cellular & molecular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/31243359","citation_count":49,"is_preprint":false},{"pmid":"25216226","id":"PMC_25216226","title":"MYD88 L265P mutation analysis helps define nodal lymphoplasmacytic lymphoma.","date":"2014","source":"Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc","url":"https://pubmed.ncbi.nlm.nih.gov/25216226","citation_count":48,"is_preprint":false},{"pmid":"33232972","id":"PMC_33232972","title":"Adaptive T-cell immunity controls senescence-prone MyD88- or CARD11-mutant B-cell lymphomas.","date":"2021","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/33232972","citation_count":47,"is_preprint":false},{"pmid":"24444466","id":"PMC_24444466","title":"CD79B and MYD88 mutations in diffuse large B-cell lymphoma.","date":"2013","source":"Human pathology","url":"https://pubmed.ncbi.nlm.nih.gov/24444466","citation_count":47,"is_preprint":false},{"pmid":"18458086","id":"PMC_18458086","title":"The scaffold MyD88 acts to couple protein kinase Cepsilon to Toll-like receptors.","date":"2008","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/18458086","citation_count":47,"is_preprint":false},{"pmid":"26217083","id":"PMC_26217083","title":"TLR4-HMGB1-, MyD88- and TRIF-dependent signaling in mouse intestinal ischemia/reperfusion injury.","date":"2015","source":"World journal of gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/26217083","citation_count":47,"is_preprint":false},{"pmid":"35769880","id":"PMC_35769880","title":"The STING1-MYD88 complex drives ACOD1/IRG1 expression and function in lethal innate immunity.","date":"2022","source":"iScience","url":"https://pubmed.ncbi.nlm.nih.gov/35769880","citation_count":45,"is_preprint":false},{"pmid":"26261595","id":"PMC_26261595","title":"Significance of TLR4/MyD88 expression in breast cancer.","date":"2015","source":"International journal of clinical and experimental pathology","url":"https://pubmed.ncbi.nlm.nih.gov/26261595","citation_count":44,"is_preprint":false},{"pmid":"17339472","id":"PMC_17339472","title":"MyD88- and Bruton's tyrosine kinase-mediated signals are essential for T cell-independent pathogen-specific IgM responses.","date":"2007","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/17339472","citation_count":43,"is_preprint":false},{"pmid":"25355920","id":"PMC_25355920","title":"Cytomegalovirus enhances macrophage TLR expression and MyD88-mediated signal transduction to potentiate inducible inflammatory responses.","date":"2014","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/25355920","citation_count":43,"is_preprint":false},{"pmid":"30650348","id":"PMC_30650348","title":"Innate Sensing through Mesenchymal TLR4/MyD88 Signals Promotes Spontaneous Intestinal Tumorigenesis.","date":"2019","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/30650348","citation_count":42,"is_preprint":false},{"pmid":"27979975","id":"PMC_27979975","title":"TLR3 downregulates expression of schizophrenia gene Disc1 via MYD88 to control neuronal morphology.","date":"2016","source":"EMBO reports","url":"https://pubmed.ncbi.nlm.nih.gov/27979975","citation_count":41,"is_preprint":false},{"pmid":"23728346","id":"PMC_23728346","title":"Differential role of MyD88 and Mal/TIRAP in TLR2-mediated gastric tumourigenesis.","date":"2013","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/23728346","citation_count":40,"is_preprint":false},{"pmid":"32005797","id":"PMC_32005797","title":"SYK is activated by mutated MYD88 and drives pro-survival signaling in MYD88 driven B-cell lymphomas.","date":"2020","source":"Blood cancer journal","url":"https://pubmed.ncbi.nlm.nih.gov/32005797","citation_count":39,"is_preprint":false},{"pmid":"19052080","id":"PMC_19052080","title":"MyD88 intrinsically regulates CD4 T-cell responses.","date":"2008","source":"Journal of virology","url":"https://pubmed.ncbi.nlm.nih.gov/19052080","citation_count":38,"is_preprint":false},{"pmid":"28701369","id":"PMC_28701369","title":"Synergistic cooperation and crosstalk between MYD88 and mutations that dysregulate CD79B and surface IgM.","date":"2017","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/28701369","citation_count":37,"is_preprint":false},{"pmid":"29358175","id":"PMC_29358175","title":"Extracellular vesicle-mediated transfer of constitutively active MyD88L265P engages MyD88wt and activates signaling.","date":"2018","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/29358175","citation_count":37,"is_preprint":false},{"pmid":"32365080","id":"PMC_32365080","title":"SPOP promotes ubiquitination and degradation of MyD88 to suppress the innate immune response.","date":"2020","source":"PLoS pathogens","url":"https://pubmed.ncbi.nlm.nih.gov/32365080","citation_count":35,"is_preprint":false},{"pmid":"30025110","id":"PMC_30025110","title":"MyD88 Deficiency Protects Against Dry Eye-Induced Damage.","date":"2018","source":"Investigative ophthalmology & visual science","url":"https://pubmed.ncbi.nlm.nih.gov/30025110","citation_count":34,"is_preprint":false},{"pmid":"33025009","id":"PMC_33025009","title":"MYD88 L265P elicits mutation-specific ubiquitination to drive NF-κB activation and lymphomagenesis.","date":"2021","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/33025009","citation_count":33,"is_preprint":false},{"pmid":"19955209","id":"PMC_19955209","title":"PYK2 interacts with MyD88 and regulates MyD88-mediated NF-kappaB activation in macrophages.","date":"2009","source":"Journal of leukocyte biology","url":"https://pubmed.ncbi.nlm.nih.gov/19955209","citation_count":33,"is_preprint":false},{"pmid":"38353638","id":"PMC_38353638","title":"Gut microbiota regulates host melatonin production through epithelial cell MyD88.","date":"2024","source":"Gut microbes","url":"https://pubmed.ncbi.nlm.nih.gov/38353638","citation_count":33,"is_preprint":false},{"pmid":"9344657","id":"PMC_9344657","title":"Genetic structure and chromosomal mapping of MyD88.","date":"1997","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/9344657","citation_count":33,"is_preprint":false},{"pmid":"35044826","id":"PMC_35044826","title":"Preneoplastic somatic mutations including MYD88L265P in lymphoplasmacytic lymphoma.","date":"2022","source":"Science advances","url":"https://pubmed.ncbi.nlm.nih.gov/35044826","citation_count":32,"is_preprint":false},{"pmid":"30301877","id":"PMC_30301877","title":"Loss of TNFAIP3 enhances MYD88L265P-driven signaling in non-Hodgkin lymphoma.","date":"2018","source":"Blood cancer journal","url":"https://pubmed.ncbi.nlm.nih.gov/30301877","citation_count":32,"is_preprint":false},{"pmid":"26388135","id":"PMC_26388135","title":"High prevalence of the MYD88 mutation in testicular lymphoma: Immunohistochemical and genetic analyses.","date":"2015","source":"Pathology international","url":"https://pubmed.ncbi.nlm.nih.gov/26388135","citation_count":32,"is_preprint":false},{"pmid":"28220253","id":"PMC_28220253","title":"MyD88 in Mycobacterium tuberculosis infection.","date":"2017","source":"Medical microbiology and immunology","url":"https://pubmed.ncbi.nlm.nih.gov/28220253","citation_count":31,"is_preprint":false},{"pmid":"30203262","id":"PMC_30203262","title":"Oncogenic MYD88 mutations in lymphoma: novel insights and therapeutic possibilities.","date":"2018","source":"Cancer immunology, immunotherapy : CII","url":"https://pubmed.ncbi.nlm.nih.gov/30203262","citation_count":31,"is_preprint":false},{"pmid":"25696843","id":"PMC_25696843","title":"Role of MYD88 in lymphoplasmacytic lymphoma diagnosis and pathogenesis.","date":"2014","source":"Hematology. American Society of Hematology. Education Program","url":"https://pubmed.ncbi.nlm.nih.gov/25696843","citation_count":31,"is_preprint":false},{"pmid":"35628381","id":"PMC_35628381","title":"MYD88 Mutations: Transforming the Landscape of IgM Monoclonal Gammopathies.","date":"2022","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/35628381","citation_count":30,"is_preprint":false},{"pmid":"25403892","id":"PMC_25403892","title":"Dendritic cell specific targeting of MyD88 signalling pathways in vivo.","date":"2014","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/25403892","citation_count":30,"is_preprint":false},{"pmid":"29502561","id":"PMC_29502561","title":"MyD88 and TLR4 Expression in Epithelial Ovarian Cancer.","date":"2018","source":"Mayo Clinic proceedings","url":"https://pubmed.ncbi.nlm.nih.gov/29502561","citation_count":27,"is_preprint":false},{"pmid":"27872207","id":"PMC_27872207","title":"Myeloid-Specific Gene Deletion of Protein Phosphatase 2A Magnifies MyD88- and TRIF-Dependent Inflammation following Endotoxin Challenge.","date":"2016","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/27872207","citation_count":27,"is_preprint":false},{"pmid":"33919485","id":"PMC_33919485","title":"Role of Adaptor Protein Myeloid Differentiation 88 (MyD88) in Post-Subarachnoid Hemorrhage Inflammation: A Systematic Review.","date":"2021","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/33919485","citation_count":27,"is_preprint":false},{"pmid":"23766530","id":"PMC_23766530","title":"MyD88 in DNA repair and cancer cell resistance to genotoxic drugs.","date":"2013","source":"Journal of the National Cancer Institute","url":"https://pubmed.ncbi.nlm.nih.gov/23766530","citation_count":26,"is_preprint":false},{"pmid":"28562479","id":"PMC_28562479","title":"Sepsis Upregulates CD14 Expression in a MyD88-Dependent and Trif-Independent Pathway.","date":"2018","source":"Shock (Augusta, Ga.)","url":"https://pubmed.ncbi.nlm.nih.gov/28562479","citation_count":25,"is_preprint":false},{"pmid":"29061802","id":"PMC_29061802","title":"MYD88 Inhibitor ST2825 Suppresses the Growth of Lymphoma and Leukaemia Cells.","date":"2017","source":"Anticancer research","url":"https://pubmed.ncbi.nlm.nih.gov/29061802","citation_count":24,"is_preprint":false},{"pmid":"24285099","id":"PMC_24285099","title":"Dual function of MyD88 in inflammation and oncogenesis: implications for therapeutic intervention.","date":"2014","source":"Current opinion in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/24285099","citation_count":23,"is_preprint":false},{"pmid":"34289811","id":"PMC_34289811","title":"Evolution of Toll, Spatzle and MyD88 in insects: the problem of the Diptera bias.","date":"2021","source":"BMC genomics","url":"https://pubmed.ncbi.nlm.nih.gov/34289811","citation_count":23,"is_preprint":false},{"pmid":"29067999","id":"PMC_29067999","title":"MyD88-dependent dendritic and epithelial cell crosstalk orchestrates immune responses to allergens.","date":"2017","source":"Mucosal immunology","url":"https://pubmed.ncbi.nlm.nih.gov/29067999","citation_count":21,"is_preprint":false},{"pmid":"28796783","id":"PMC_28796783","title":"MyD88 contribution to ocular surface homeostasis.","date":"2017","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/28796783","citation_count":21,"is_preprint":false},{"pmid":"31935288","id":"PMC_31935288","title":"Expression of the prosurvival kinase HCK requires PAX5 and mutated MYD88 signaling in MYD88-driven B-cell lymphomas.","date":"2020","source":"Blood advances","url":"https://pubmed.ncbi.nlm.nih.gov/31935288","citation_count":21,"is_preprint":false},{"pmid":"27480067","id":"PMC_27480067","title":"HMGB1 facilitates hypoxia-induced vWF upregulation through TLR2-MYD88-SP1 pathway.","date":"2016","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/27480067","citation_count":20,"is_preprint":false},{"pmid":"33002631","id":"PMC_33002631","title":"Abnormal brain structure and behavior in MyD88-deficient mice.","date":"2020","source":"Brain, behavior, and immunity","url":"https://pubmed.ncbi.nlm.nih.gov/33002631","citation_count":19,"is_preprint":false},{"pmid":"23235763","id":"PMC_23235763","title":"Mutational and expressional analyses of MYD88 gene in common solid cancers.","date":"2012","source":"Tumori","url":"https://pubmed.ncbi.nlm.nih.gov/23235763","citation_count":19,"is_preprint":false},{"pmid":"26881204","id":"PMC_26881204","title":"MyD88 Polymorphisms and Association with Susceptibility to Salmonella Pullorum.","date":"2015","source":"BioMed research international","url":"https://pubmed.ncbi.nlm.nih.gov/26881204","citation_count":19,"is_preprint":false},{"pmid":"38785969","id":"PMC_38785969","title":"MyD88 and Its Inhibitors in Cancer: Prospects and Challenges.","date":"2024","source":"Biomolecules","url":"https://pubmed.ncbi.nlm.nih.gov/38785969","citation_count":18,"is_preprint":false},{"pmid":"27528076","id":"PMC_27528076","title":"Role of MyD88 in adenovirus keratitis.","date":"2016","source":"Immunology and cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/27528076","citation_count":18,"is_preprint":false},{"pmid":"31039009","id":"PMC_31039009","title":"Hepatic MyD88 regulates liver inflammation by altering synthesis of oxysterols.","date":"2019","source":"American journal of physiology. Endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/31039009","citation_count":18,"is_preprint":false},{"pmid":"26546866","id":"PMC_26546866","title":"Polysaccharopeptide exerts immunoregulatory effects via MyD88-dependent signaling pathway.","date":"2015","source":"International journal of biological macromolecules","url":"https://pubmed.ncbi.nlm.nih.gov/26546866","citation_count":18,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":50906,"output_tokens":9019,"usd":0.144002,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":18950,"output_tokens":5704,"usd":0.118675,"stage2_stop_reason":"end_turn"},"total_usd":0.262677,"stage1_batch_id":"msgbatch_013a8chtv3AWyTqv4z4sEF4C","stage2_batch_id":"msgbatch_01AHsuW63vinsvuTgzmQ3n62","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1998,\n      \"finding\": \"MyD88 functions as an adaptor protein in IL-1 signaling: it forms homodimers via DD-DD and Toll-Toll interactions, co-immunoprecipitates with the IL-1R signaling complex in an IL-1-dependent manner, and overexpression activates JNK and NF-κB through its death domain. A point mutation (F56N/MyD88-lpr) that prevents DD dimerization blocks these activities. Dominant negative versions of TRAF6 and IRAK inhibit MyD88-induced NF-κB activation.\",\n      \"method\": \"Co-immunoprecipitation, overexpression/dominant-negative constructs, point mutagenesis, reporter assays in 293 cells\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — multiple orthogonal methods (Co-IP, mutagenesis, reporter assays) in a single focused study; foundational mechanism paper replicated by subsequent work\",\n      \"pmids\": [\"9575168\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"MyD88 is essential for LPS (endotoxin) responses downstream of TLR4: MyD88 knockout mice lack LPS-induced shock, B-cell proliferation, and cytokine secretion by macrophages and fibroblasts. However, NF-κB and MAP kinase activation are not abolished in MyD88-KO cells, demonstrating a MyD88-independent pathway also emanates from TLR4.\",\n      \"method\": \"MyD88 knockout mouse model; LPS challenge; cytokine measurement; NF-κB/MAPK assays\",\n      \"journal\": \"Immunity\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — clean genetic KO with multiple defined phenotypic readouts; independently replicated across many subsequent studies\",\n      \"pmids\": [\"10435584\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"MyD88 is required for LPS-induced cytokine production from dendritic cells but not for LPS-induced functional DC maturation (upregulation of costimulatory molecules). Both pathways originate from the TLR4 intracytoplasmic region, as both were abolished in C3H/HeJ (TLR4 mutant) DCs. MyD88 is absolutely required for TLR9 (bacterial DNA)-induced DC maturation, demonstrating differential pathway requirements across TLRs.\",\n      \"method\": \"MyD88-deficient and TLR4-mutant mouse DCs; LPS and CpG stimulation; costimulatory molecule upregulation; APC activity assays; cytokine measurement\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic KO with multiple orthogonal phenotypic readouts; discriminates two downstream pathways of TLR4\",\n      \"pmids\": [\"11313410\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"Taxol (paclitaxel) LPS-mimetic activity requires both TLR4 and MyD88 for TNF and NO production and NF-κB-driven gene expression. Macrophages from TLR4-null or MyD88-KO mice produced minimal TNF/NO upon Taxol. However, Taxol-induced MAPK activation and NF-κB nuclear translocation were preserved in MyD88-KO macrophages (with slight kinetic delay), indicating a TLR4-dependent/MyD88-independent pathway also exists for these signals.\",\n      \"method\": \"TLR4-deficient and MyD88-KO primary macrophages; dominant-negative MyD88 transfection; TNF/NO measurement; NF-κB reporter/luciferase assay; MAPK activation assay\",\n      \"journal\": \"European journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple genetic models (KO and dominant-negative) with several orthogonal readouts; discriminates MyD88-dependent and -independent outputs\",\n      \"pmids\": [\"11500829\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"Peptidoglycan (PGN) and micrococci signal through TLR2 to induce IL-8 via a sequential pathway TLR2→MyD88→IRAK→TRAF6→NIK→IKK→NF-κB. Dominant-negative MyD88 completely blocked PGN/micrococcus-induced NF-κB activation and IL-8 gene expression, positioning MyD88 immediately downstream of TLR2.\",\n      \"method\": \"Dominant-negative expression constructs (MyD88, IRAK, NIK, IKK, TRAF6) in HEK293 cells expressing TLR2/CD14; NF-κB reporter assay; IL-8 gene expression\",\n      \"journal\": \"Infection and immunity\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — epistasis established by systematic dominant-negative analysis of each pathway component; multiple components tested\",\n      \"pmids\": [\"11254583\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"MyD88 mediates a post-transcriptional mechanism downstream of IFN-γ receptor signaling: IFN-γ stimulation induces physical association between IFN-γR1 and MyD88. MyD88 increases the mRNA half-life (not synthesis) of IFN-γ-induced TNF and IP-10 transcripts via activation of mixed-lineage kinase 3 and p38 MAPK, requiring an AU-rich element in the 3′ UTR.\",\n      \"method\": \"Co-immunoprecipitation of IFN-γR1 with MyD88; mRNA stability assay; MyD88-deficient cells; kinase inhibitors; RNA half-life measurement\",\n      \"journal\": \"Nature immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — reciprocal Co-IP plus functional mRNA stability assays and genetic KO, single lab with multiple orthogonal methods\",\n      \"pmids\": [\"16491077\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"MyD88-5 (a vertebrate MyD88 family member) is preferentially expressed in neurons, co-localizes with mitochondria and JNK3, and recruits JNK3 from cytosol to mitochondria. Co-immunoprecipitation confirmed MyD88-5 interacts with JNK3. Hippocampal neurons from MyD88-5-deficient mice are protected from oxygen-glucose deprivation-induced death, whereas MyD88-5-null macrophages respond normally to microbial products.\",\n      \"method\": \"MyD88-5/GFP BAC transgenic mice; co-immunoprecipitation of MyD88-5 with JNK3; mitochondrial co-fractionation; MyD88-5-KO neurons; oxygen-glucose deprivation assay\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — Co-IP, subcellular fractionation, transgenic/KO models with defined neuronal death phenotype; multiple orthogonal methods in one study\",\n      \"pmids\": [\"17724133\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"MyD88 acts as a scaffold to couple PKCε to TLRs: LPS-induced PKCε phosphorylation at Ser-346 and Ser-368, 14-3-3β binding, and recruitment to TLR4 are all MyD88-dependent. MyD88 overexpression causes constitutive PKCε phosphorylation; acute MyD88 knockdown abolishes Ser-346 phosphorylation. PKCε phosphorylation at these sites is required for TLR4- and TLR2-induced NF-κB activation and IκB degradation.\",\n      \"method\": \"MyD88-KO mouse embryo fibroblasts and macrophages; MyD88 knockdown in 293 cells; MyD88 overexpression; PKCε phosphorylation assays; TLR4 co-immunoprecipitation; NF-κB reporter assay in PKCε-/- reconstituted cells\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple genetic and biochemical approaches (KO, KD, OE, Co-IP, functional reconstitution) converging on same mechanism\",\n      \"pmids\": [\"18458086\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"MyD88 interacts with PI3K p85 subunit via a YXXM motif in its TIR domain, and this interaction negatively regulates TLR4 signaling. A YXXM→YXXA mutant MyD88 bound more strongly to p85, TLR4, and wild-type MyD88, yet was less active than wild-type, suggesting sustained MyD88/PI3K interaction at the TLR4 signaling platform limits downstream output. LPS-induced Akt phosphorylation was blunted in MyD88−/− macrophages.\",\n      \"method\": \"Co-immunoprecipitation of MyD88 variants with PI3K p85, TLR4, and wild-type MyD88; MyD88 TIR/DD domain deletion and YXXM point mutants; Akt phosphorylation in MyD88-KO macrophages\",\n      \"journal\": \"Journal of leukocyte biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — Co-IP with domain mutants and KO macrophages, single lab; mechanistic conclusion (negative regulation) is supported but indirect\",\n      \"pmids\": [\"19289601\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"Protein kinase D1 (PKD1) is activated downstream of MyD88 and IRAK4/1 (but not TRAF6) in TLR signaling. PKD1 is required for MyD88-dependent TRAF6 ubiquitination, TAK1 activation, MAPK and transcription factor activation, and proinflammatory gene expression. PKD1 does not contribute to TRIF-dependent type I IFN responses.\",\n      \"method\": \"PKD1 knockdown in macrophages and DCs; TLR ligand stimulation; TRAF6 ubiquitination assay; TAK1, MAPK and NF-κB activation assays; cytokine/IFN measurement\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — epistasis established by RNAi knockdown with multiple downstream readouts; single lab but several orthogonal assays\",\n      \"pmids\": [\"19414785\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"PYK2 interacts with MyD88 (requiring MyD88's death domain) in vitro and in macrophages; this interaction is increased upon LPS stimulation. PYK2-deficient macrophages show reduced IκB phosphorylation/degradation, decreased NF-κB activation, and reduced IL-1β expression in response to LPS, placing PYK2 as a co-regulator upstream of NF-κB via interaction with MyD88.\",\n      \"method\": \"Co-immunoprecipitation of PYK2 with MyD88 in vitro and in macrophages; PYK2-KO macrophages; LPS stimulation; IκB phosphorylation/degradation; NF-κB activation assay\",\n      \"journal\": \"Journal of leukocyte biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP with domain requirement plus KO functional assay; single lab, two orthogonal methods\",\n      \"pmids\": [\"19955209\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"The L265P mutation in the MYD88 TIR domain is a gain-of-function oncogenic driver in ABC DLBCL. The MYD88 L265P mutant spontaneously assembles a protein complex containing IRAK1 and IRAK4, leading to constitutive IRAK4 kinase activity, IRAK1 phosphorylation, NF-κB activation, JAK kinase activation of STAT3, and secretion of IL-6, IL-10, and IFN-β. Wild-type MYD88 did not substitute for L265P in sustaining ABC DLBCL cell survival.\",\n      \"method\": \"RNA interference screening; RNA resequencing; co-immunoprecipitation of MYD88 L265P with IRAK1/4; kinase activity assays; IRAK1 phosphorylation; NF-κB/STAT3 signaling assays; cytokine secretion measurement; rescue experiments with WT vs. L265P MYD88\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — multiple orthogonal methods (Co-IP, kinase assay, RNAi, rescue) in one rigorous study; independently replicated by multiple subsequent labs\",\n      \"pmids\": [\"21179087\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Two naturally occurring human MYD88 death-domain variants, S34Y and R98C, show severely reduced NF-κB activation due to impaired MyD88 homo-oligomerization and reduced IRAK4 interaction. Structural modeling identifies Ser-34 and Arg-98 as key residues for Myddosome assembly (the DD complex of MyD88, IRAK4, and IRAK2/1). MyD88 TIR domain and IRAK4 kinase domain modulate DD homo-oligomerization. S34Y and R98C differentially impair signaling through IL-1R, TLR2, TLR4, TLR5, and TLR7, but not TLR9.\",\n      \"method\": \"In vitro cellular NF-κB activation assay; co-immunoprecipitation for homo-oligomerization and IRAK4 binding; structural modeling; receptor-specific signaling assays with TLR2/4/5/7/9 and IL-1R\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — mutagenesis, Co-IP, structural modeling, and multiple receptor-specific functional assays in one study\",\n      \"pmids\": [\"20966070\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"IRAK1 and IRAK4 directly phosphorylate Mal (MyD88 adaptor-like/TIRAP), promoting its ubiquitination and proteasomal degradation. MyD88 itself is not a substrate for either IRAK and does not undergo degradation. This process negatively regulates TLR2 and TLR4 signaling.\",\n      \"method\": \"In vitro kinase assay with IRAK1/4; co-expression and immunoprecipitation; kinase-inactive IRAK mutants; LPS-induced ubiquitination assay; IRAK1/4 inhibitor; IRAK1/4 knockdown\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — direct in vitro kinase assay with mutagenesis controls; negative result for MyD88 as substrate is itself mechanistically informative\",\n      \"pmids\": [\"20400509\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"MYD88 L265P triggers IRAK-mediated NF-κB signaling and is a somatic gain-of-function mutation found in ~91% of Waldenström's macroglobulinemia/lymphoplasmacytic lymphoma patients. Inhibition of MYD88 signaling reduced IκBα and NF-κB p65 phosphorylation and NF-κB nuclear translocation in WM cells expressing MYD88 L265P.\",\n      \"method\": \"Whole-genome sequencing; Sanger sequencing validation; MYD88 signaling inhibition assay; IκBα/NF-κB phosphorylation and nuclear staining in WM cells\",\n      \"journal\": \"The New England journal of medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genomic discovery plus functional inhibition experiment; replicated across multiple independent cohorts\",\n      \"pmids\": [\"22931316\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"MYD88 mediates an NF-κB-independent pathway downstream of IL-1β in endothelial cells: ARNO directly binds MYD88, and IL-1β signals through MYD88→ARNO→ARF6 to disrupt endothelial barrier function and vascular stability. This pathway is distinct from the canonical NF-κB transcriptional pathway.\",\n      \"method\": \"Direct binding assay (ARNO–MYD88 interaction); human endothelial cell model; NF-κB-independent assay; ARF6/ARNO functional experiments; animal models of inflammatory arthritis\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — direct binding demonstrated, NF-κB independence established, functional animal model; single lab with multiple methods\",\n      \"pmids\": [\"23143332\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"In keratinocytes, oncogenic RAS establishes an autocrine signaling loop through IL-1α→IL-1R→MyD88 that leads to IκBα phosphorylation and NF-κB activation, driving proinflammatory gene expression and impairing differentiation. MyD88 exerts a cell-intrinsic function in RAS-mediated transformation; MyD88-/- RAS-expressing keratinocytes form only a few small tumors in orthotopic grafts.\",\n      \"method\": \"MyD88-/- and IL-1R-/- mice; oncogenic RAS expression in keratinocytes; orthotopic graft model; pharmacological and genetic IL-1α/NF-κB blockade; proinflammatory gene expression analysis\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic and pharmacological epistasis with multiple orthogonal approaches; cell-intrinsic function demonstrated by in vivo grafting\",\n      \"pmids\": [\"22908325\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"TRAF6 and Pellino1/2 E3 ligases redundantly generate K63-linked ubiquitin chains for MyD88-dependent IL-1 signaling. In TRAF6/Pellino1/Pellino2 triple-KO cells, IL-1-induced K63-Ub chains, ubiquitylation of IRAK1, IRAK4, and MyD88, and TAK1 activation are abolished. Pellino1-generated K63-Ub chains activate TAK1 complex with similar efficiency to TRAF6-generated chains in vitro.\",\n      \"method\": \"TRAF6/Pellino1/Pellino2 triple-KO cells; E3 ligase-inactive TRAF6 knockin mice; ubiquitination assays; TAK1 activation assay in vitro; cytokine measurement; osteoclast differentiation assay\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — triple genetic KO combined with in vitro reconstitution and knockin mice; multiple orthogonal methods rigorously establish redundancy\",\n      \"pmids\": [\"28404732\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"MyD88 promotes myoblast fusion in a cell-autonomous manner. MyD88 protein levels increase during in vitro myogenesis and in conditions of skeletal muscle growth. Deletion of MyD88 impairs fusion without affecting myoblast survival, proliferation, or differentiation. MyD88 regulates non-canonical NF-κB and canonical Wnt signaling during myogenesis and promotes overload-induced myofiber hypertrophy.\",\n      \"method\": \"MyD88 conditional deletion in myoblasts; in vitro myogenesis assay; overexpression of MyD88 in exogenous myoblasts; muscle regeneration and overload hypertrophy in vivo mouse models; NF-κB and Wnt signaling assays\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — conditional KO plus overexpression with multiple in vitro and in vivo readouts; identifies distinct signaling outputs (non-canonical NF-κB, Wnt)\",\n      \"pmids\": [\"29158520\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"MyD88 L265P protein is present in extracellular vesicles (EVs) shed from WM cells and can be transferred into recipient mast cells and macrophages. Transferred MyD88 L265P recruits endogenous wild-type MyD88, triggering proinflammatory signaling in the absence of receptor activation. This transfer was also observed in vivo in mice and MyD88-loaded EVs were detected in bone marrow aspirates of WM patients.\",\n      \"method\": \"EV isolation and characterization; confocal microscopy of EV uptake; co-immunoprecipitation of MyD88 L265P with endogenous MyD88; signaling assays in recipient cells; in vivo mouse EV injection; patient bone marrow aspirate analysis\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal methods (Co-IP, imaging, functional signaling, in vivo) in one study demonstrating novel intercellular transfer mechanism\",\n      \"pmids\": [\"29358175\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"BANK1 directly binds MyD88 (and TRAF6) via its TIR domain, as demonstrated by co-immunoprecipitation. The natural BANK1-40C variant shows increased binding to MyD88. BANK1 co-localizes with TLR7/9, TRAF6, and MyD88 in mouse splenic B cells and co-localization increases after TLR7/9 agonist stimulation.\",\n      \"method\": \"Co-immunoprecipitation of BANK1 with MyD88 and TRAF6; domain deletion and point mutation experiments; confocal co-localization in mouse splenic B cells; TLR7/9 agonist stimulation\",\n      \"journal\": \"Cellular & molecular immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — Co-IP with domain mapping and co-localization; single lab with two orthogonal methods but limited functional reconstitution\",\n      \"pmids\": [\"31243359\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"SPOP (a Cullin 3-based ubiquitin ligase adaptor) recognizes the intermediate domain of MyD88 and promotes its proteasomal degradation, negatively regulating NF-κB pathway activity. Knockdown or genetic ablation of SPOP leads to elevated MyD88 protein and increased IL-1β production upon LPS challenge in macrophages. Spop-deficient mice are more susceptible to Salmonella infection.\",\n      \"method\": \"Co-immunoprecipitation of SPOP with MyD88; domain mapping of MyD88 interaction; SPOP knockdown and KO; proteasome inhibitor experiments; NF-κB/IL-1β functional assays; Salmonella infection model\",\n      \"journal\": \"PLoS pathogens\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP with domain mapping, genetic KO, proteasome pathway confirmed, and in vivo infection model; multiple orthogonal methods\",\n      \"pmids\": [\"32365080\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Mutated MYD88 L265P activates SYK (a BCR signaling component): p-SYK co-immunoprecipitates with MYD88 in MYD88-mutated lymphoma cells, and confocal microscopy confirms co-localization. MYD88 knockdown or signaling inhibition abrogates SYK activation, while expression of mutated (but not wild-type) MYD88 amplifies p-SYK. SYK supports p-STAT3 and p-AKT signaling in MYD88-mutated cells.\",\n      \"method\": \"Co-immunoprecipitation of p-SYK with MYD88; confocal co-localization; MYD88 knockdown; MYD88 signaling inhibitor; expression of mutant vs WT MYD88; SYK inhibitor/knockdown; cell viability assays\",\n      \"journal\": \"Blood cancer journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal Co-IP plus confocal co-localization and genetic/pharmacological perturbations; single lab, multiple methods\",\n      \"pmids\": [\"32005797\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"E3 ligase RNF138 catalyzes K63-linked non-proteolytic polyubiquitination of MYD88 L265P (but not wild-type MYD88), which enhances IRAK recruitment and NF-κB activation. A20 mediates K48-linked ubiquitination of RNF138 for proteasomal degradation, acting as a counter-regulatory mechanism. Mutation of MYD88 L265P ubiquitination sites or RNF138 knockdown abolishes constitutive NF-κB activation.\",\n      \"method\": \"Ubiquitination assay distinguishing K63 vs K48 linkage; RNF138 knockdown; MYD88 L265P ubiquitination site mutagenesis; co-immunoprecipitation; NF-κB activity assays; lymphoma growth experiments\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — in vitro ubiquitination assays, site-directed mutagenesis, and functional NF-κB readouts; mutation-specific biochemical mechanism rigorously established\",\n      \"pmids\": [\"33025009\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Pathological tau (pTau) activates IL-1β via a MyD88- and NLRP3-ASC-dependent pathway in myeloid cells/microglia. Deletion of MyD88 prevents both IL-1β expression and activation in the hTau mouse model of tauopathy.\",\n      \"method\": \"MyD88 deletion in hTau mice; NLRP3/ASC/caspase-1 inhibition; inflammasome activation assays; IL-1β measurement; mouse behavioral/cognitive assessment\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic deletion with defined molecular and behavioral readouts; single lab; pathway placement established by epistasis\",\n      \"pmids\": [\"34551296\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"The IRAK4 scaffold (independent of its kinase activity) is required for TRAF6 activation by both MYD88 and TRIF downstream of TLR4, integrating the two TLR4 signaling pathways. IRAK4 kinase activity is essential for MYD88-dependent signaling specifically.\",\n      \"method\": \"IRAK4 knockout and kinase-inactive/scaffold mutant reconstitution in TLR4-stimulated cells; TRAF6 activation assays; MYD88 and TRIF signaling readouts\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic KO combined with reconstitution of scaffold vs kinase-inactive IRAK4 mutants; rigorously dissects scaffold vs enzymatic roles\",\n      \"pmids\": [\"35977521\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"MYD88 in osteocytes directly drives bacterially-induced osteolysis via RANKL upregulation. Osteocyte-specific MYD88 deletion protects against PAMP-induced calvarial osteolysis and P. gingivalis-driven alveolar bone resorption. Mechanistically, osteocyte MYD88 activation increases CREB and STAT3 binding to RANKL enhancers and suppresses K48-ubiquitination of CREB/CBP and STAT3.\",\n      \"method\": \"Osteocyte-specific MYD88 KO and restoration mice; calvarial PAMP injection model; oral P. gingivalis infection model; RANKL expression assay; ChIP for CREB/STAT3 at Rankl enhancers; ubiquitination assay; systemic MYD88 inhibitor treatment\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — cell-type-specific KO and restoration in vivo, ChIP, ubiquitination assays, and pharmacological inhibition; multiple orthogonal methods; replicated in two disease models\",\n      \"pmids\": [\"36333322\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"MYD88 directly blocks autophagic degradation of STING1, causing subsequent IRF3/JUN-mediated ACOD1 (IRG1) gene transcription and itaconate production in myeloid cells following TLR4 signaling. CGAS (the DNA sensor) does not contribute to this STING1-dependent ACOD1 expression; MYD88 is the key adaptor. STING1 deletion in myeloid cells abolishes ACOD1/itaconate production.\",\n      \"method\": \"STING1 and MYD88 deletion/interaction studies; cyclic dinucleotide stimulation; autophagic degradation assay; ACOD1 expression and itaconate measurement; myeloid-specific STING1 KO mice; endotoxemia and sepsis models\",\n      \"journal\": \"iScience\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic KO, direct MYD88-STING1 interaction implied by functional epistasis, multiple readouts; single lab\",\n      \"pmids\": [\"35769880\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"MyD88 has a modular gene structure with an N-terminal death domain (encoded by exon 1) and C-terminal TIR (Toll/IL-1 receptor) domain. It is an evolutionarily conserved, widely expressed gene mapped to mouse chromosome 9 distal region and human chromosome 3p22-p21.3.\",\n      \"method\": \"cDNA cloning; gene structure analysis (5 exons); interspecific backcross mapping; somatic cell hybrid mapping; Northern blot; RT-PCR\",\n      \"journal\": \"Genomics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct structural characterization by cloning and mapping with multiple analytical methods; foundational structural paper\",\n      \"pmids\": [\"9344657\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"In adenovirus keratitis, MyD88 co-immunoprecipitates with Src kinase in infected mouse corneas and human corneal fibroblasts, and MyD88 inhibitory peptide reduces Src phosphorylation. TLR2 and TLR9 act synergistically; MyD88-/- mice show markedly reduced keratitis and inflammatory cytokine expression.\",\n      \"method\": \"Co-immunoprecipitation of MyD88 with Src kinase; MyD88 inhibitory peptide; MyD88-/-, TLR2-/-, TLR9-/-, and TLR2/9 double-KO mouse infection model; Src phosphorylation assay; cytokine expression\",\n      \"journal\": \"Immunology and cell biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP plus genetic KO and pharmacological inhibition; single lab with multiple genetic models\",\n      \"pmids\": [\"27528076\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"MyD88 is a cytoplasmic adaptor protein with an N-terminal death domain and C-terminal TIR domain that serves as the universal scaffold for nearly all TLR and IL-1R/IL-18R family signaling: upon receptor activation it homo-oligomerizes via DD-DD and TIR-TIR interactions, recruits IRAK4 and IRAK1/2 into the 'Myddosome' complex (assembly requiring specific DD residues), leading to TRAF6/Pellino-dependent K63-ubiquitin chain formation, TAK1 activation, and downstream NF-κB and MAPK activation; it also scaffolds PKCε and PYK2, couples IFN-γR1 to post-transcriptional mRNA stabilization via p38, and mediates a non-canonical MYD88→ARNO→ARF6 pathway for vascular permeability; the oncogenic L265P TIR-domain mutation causes spontaneous Myddosome assembly, constitutive IRAK4 kinase activation, NF-κB/STAT3/JAK signaling, and is selectively polyubiquitinated by RNF138 on K63 linkages to further amplify signaling; MyD88 abundance is controlled by SPOP-mediated proteasomal degradation and by transfer via extracellular vesicles between cells.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"MYD88 is a cytoplasmic adaptor with an N-terminal death domain (DD) and C-terminal TIR domain that serves as the central signaling scaffold for the IL-1R and Toll-like receptor (TLR) families [#0, #28]. Upon ligand engagement it homodimerizes through DD-DD and TIR-TIR interactions, couples to the receptor, and activates JNK and NF-\\u03baB; mutations that block DD dimerization abolish this activity [#0]. MYD88 nucleates assembly of the 'Myddosome', recruiting IRAK4 and IRAK1/2 via DD interactions that depend on specific residues such as Ser-34 and Arg-98 [#12], whereupon IRAK4 kinase activity drives downstream signaling while the IRAK4 scaffold function integrates MYD88- and TRIF-dependent arms of TLR4 [#25]. Signal propagation requires K63-linked polyubiquitin chains generated redundantly by TRAF6 and Pellino1/2, which ubiquitinate IRAK1, IRAK4 and MYD88 itself to activate TAK1 and downstream MAPK/NF-\\u03baB cascades [#17], with PKD1 acting downstream of MYD88/IRAK to license TRAF6 ubiquitination [#9]. Genetic studies established MYD88 as essential for responses to LPS via TLR4, peptidoglycan via TLR2, and CpG DNA via TLR9, while revealing parallel MYD88-independent TLR4 outputs [#1, #2, #4]. Beyond canonical NF-\\u03baB signaling, MYD88 scaffolds PKC\\u03b5 and PYK2 to TLR4 [#7, #10], couples IFN-\\u03b3R1 to p38-dependent post-transcriptional stabilization of TNF and IP-10 mRNAs [#5], and drives a non-canonical IL-1\\u03b2\\u2192MYD88\\u2192ARNO\\u2192ARF6 pathway controlling endothelial barrier function [#15]. MYD88 abundance is restrained by SPOP/Cullin-3-mediated proteasomal degradation [#21]. The recurrent TIR-domain L265P mutation is a gain-of-function oncogenic driver in ABC-DLBCL and Waldenstr\\u00f6m's macroglobulinemia: it spontaneously assembles IRAK1/IRAK4 complexes, producing constitutive IRAK4 kinase activity, NF-\\u03baB and JAK/STAT3 signaling, and SYK activation [#11, #14, #22], is selectively K63-polyubiquitinated by RNF138 to amplify signaling [#23], and can be transferred between cells via extracellular vesicles to recruit endogenous wild-type MYD88 [#19]. MYD88 also functions in non-immune contexts including myoblast fusion via non-canonical NF-\\u03baB and Wnt signaling [#18], RAS-driven keratinocyte transformation [#16], osteocyte-driven osteolysis through RANKL [#26], and tauopathy-associated inflammasome activation [#24].\",\n  \"teleology\": [\n    {\n      \"year\": 1997,\n      \"claim\": \"Establishing the modular DD-TIR architecture of MYD88 provided the structural framework for understanding how it would later be shown to bridge receptors and downstream kinases.\",\n      \"evidence\": \"cDNA cloning, gene structure analysis, and chromosomal mapping\",\n      \"pmids\": [\"9344657\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Did not establish function of either domain\", \"No interaction partners identified at this stage\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"Demonstrating that MYD88 homodimerizes via its death domain and activates NF-\\u03baB/JNK downstream of the IL-1R established it as an adaptor that transmits receptor signals to TRAF6 and IRAK.\",\n      \"evidence\": \"Co-IP, dominant-negative and point mutants, reporter assays in 293 cells\",\n      \"pmids\": [\"9575168\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Stoichiometry and ordered assembly of the complex not resolved\", \"Did not address TLR signaling\"]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"Genetic knockout showed MYD88 is essential for LPS/TLR4-driven inflammation yet revealed a parallel MYD88-independent pathway, defining the bifurcation of TLR4 signaling.\",\n      \"evidence\": \"MyD88-knockout mice, LPS challenge, cytokine and NF-\\u03baB/MAPK assays\",\n      \"pmids\": [\"10435584\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Identity of the MYD88-independent adaptor not defined here\", \"Did not map which TLRs strictly require MYD88\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Comparative TLR studies positioned MYD88 immediately downstream of TLR2 in a defined NF-\\u03baB cascade and showed differential MYD88 requirements across TLR4, TLR9 and distinct DC outputs.\",\n      \"evidence\": \"Dominant-negative epistasis in HEK293/TLR2 cells and MyD88/TLR4-deficient DCs and macrophages\",\n      \"pmids\": [\"11254583\", \"11313410\", \"11500829\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism distinguishing MYD88-dependent and -independent DC maturation unresolved\", \"Did not address receptor-proximal complex assembly\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Discovery that MYD88 associates with IFN-\\u03b3R1 and stabilizes cytokine mRNAs via p38 extended its role beyond canonical NF-\\u03baB transcription to post-transcriptional control.\",\n      \"evidence\": \"Reciprocal Co-IP, mRNA half-life assays, MyD88-deficient cells, kinase inhibitors\",\n      \"pmids\": [\"16491077\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct vs indirect IFN-\\u03b3R1\\u2013MYD88 binding not resolved\", \"Trans-acting AU-rich element-binding effectors not identified\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Characterization of the neuron-enriched MYD88-5 family member at mitochondria with JNK3 showed MYD88-family proteins can act outside microbial immunity in neuronal death.\",\n      \"evidence\": \"BAC transgenic and KO mice, Co-IP with JNK3, mitochondrial fractionation, oxygen-glucose deprivation\",\n      \"pmids\": [\"17724133\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Relationship of MYD88-5 to canonical MYD88 signaling unclear\", \"Mechanism of JNK3 mitochondrial recruitment not detailed\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Showing MYD88 scaffolds PKC\\u03b5 phosphorylation and recruitment to TLR4 broadened the adaptor's role to organizing additional kinases required for NF-\\u03baB activation.\",\n      \"evidence\": \"MyD88 KO/KD/OE, PKC\\u03b5 phosphorylation assays, TLR4 Co-IP, reconstitution in PKC\\u03b5-/- cells\",\n      \"pmids\": [\"18458086\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether PKC\\u03b5 binds MYD88 directly not established\", \"Position of PKC\\u03b5 relative to the Myddosome unresolved\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Identification of PI3K p85, PKD1 and PYK2 as MYD88-associated regulators refined the proximal signaling network, including a negative-regulatory MYD88/PI3K interaction.\",\n      \"evidence\": \"Co-IP with domain/motif mutants, RNAi knockdown, KO macrophages, TRAF6 ubiquitination and NF-\\u03baB readouts\",\n      \"pmids\": [\"19289601\", \"19414785\", \"19955209\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Indirect support for PI3K negative regulation\", \"Direct vs scaffolded interactions not all resolved\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Defining DD residues required for Myddosome assembly and showing that the L265P TIR mutation drives spontaneous IRAK1/4 assembly transformed MYD88 from a normal adaptor into a defined oncogenic driver.\",\n      \"evidence\": \"Structural modeling, mutagenesis, Co-IP, RNAi/rescue, kinase and NF-\\u03baB/STAT3 assays in ABC-DLBCL\",\n      \"pmids\": [\"20966070\", \"21179087\", \"20400509\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"High-resolution structure of mutant Myddosome not provided\", \"Why L265P specifically destabilizes the autoinhibited state unclear\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Linking MYD88 L265P to Waldenstr\\u00f6m's macroglobulinemia and uncovering non-canonical (ARNO/ARF6 vascular, RAS-keratinocyte) functions expanded the disease and signaling scope of the adaptor.\",\n      \"evidence\": \"Whole-genome sequencing of WM, MYD88 inhibition in WM cells; direct ARNO binding assays; MyD88/IL-1R KO RAS keratinocyte grafts\",\n      \"pmids\": [\"22931316\", \"23143332\", \"22908325\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of ARNO\\u2013MYD88 binding not resolved\", \"How L265P selects NF-\\u03baB vs alternative outputs unclear\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Triple-knockout and reconstitution work resolved that TRAF6 and Pellino1/2 redundantly build the K63-ubiquitin chains that ubiquitinate IRAK1/4 and MYD88 to activate TAK1.\",\n      \"evidence\": \"TRAF6/Pellino1/2 triple-KO cells, ligase-dead TRAF6 knockin mice, in vitro TAK1 activation\",\n      \"pmids\": [\"28404732\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Relative physiological contribution of each ligase across cell types unresolved\", \"Chain architecture on MYD88 itself not detailed\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Demonstrating cell-autonomous MYD88 control of myoblast fusion via non-canonical NF-\\u03baB and Wnt showed a developmental role distinct from immune signaling.\",\n      \"evidence\": \"Conditional KO and overexpression, in vitro myogenesis, overload hypertrophy models\",\n      \"pmids\": [\"29158520\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Upstream receptor driving myogenic MYD88 unknown\", \"Direct effectors linking MYD88 to Wnt unidentified\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Showing that L265P MYD88 packaged in extracellular vesicles can transfer between cells and recruit endogenous wild-type MYD88 revealed a receptor-independent, intercellular mode of oncogenic signaling.\",\n      \"evidence\": \"EV isolation, confocal uptake, Co-IP, in vivo injection, patient bone marrow analysis\",\n      \"pmids\": [\"29358175\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Efficiency and physiological extent of transfer unclear\", \"Whether recipient signaling sustains transformation not shown\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Identifying SPOP-mediated degradation, BANK1 binding, and L265P-driven SYK activation defined both turnover control of MYD88 and additional partners shaping pathway output.\",\n      \"evidence\": \"Co-IP with domain mapping, SPOP KO/proteasome inhibition with Salmonella model; BANK1 Co-IP/co-localization; p-SYK Co-IP and perturbation in mutant lymphoma\",\n      \"pmids\": [\"32365080\", \"31243359\", \"32005797\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct vs indirect MYD88\\u2013SYK association unresolved\", \"Functional consequence of BANK1\\u2013MYD88 binding limited\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Discovery of RNF138-catalyzed mutation-specific K63-ubiquitination, with A20 counter-regulation, and a MYD88/NLRP3 axis in tauopathy refined mechanisms amplifying or extending MYD88 signaling.\",\n      \"evidence\": \"Linkage-specific ubiquitination assays, RNF138 knockdown and site mutagenesis, NF-\\u03baB readouts; MyD88 deletion in hTau mice\",\n      \"pmids\": [\"33025009\", \"34551296\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Why RNF138 selects mutant over wild-type MYD88 not fully explained\", \"Whether MYD88 acts upstream of inflammasome assembly directly unclear\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Dissecting IRAK4 scaffold vs kinase roles, osteocyte MYD88-driven RANKL/osteolysis, and a MYD88\\u2192STING1\\u2192ACOD1 itaconate axis revealed how MYD88 integrates distinct downstream programs in different cell types.\",\n      \"evidence\": \"IRAK4 scaffold/kinase-dead reconstitution; osteocyte-specific KO/restoration with ChIP and ubiquitination assays; STING1/MYD88 deletion and itaconate measurement\",\n      \"pmids\": [\"35977521\", \"36333322\", \"35769880\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct MYD88\\u2013STING1 interaction not biochemically confirmed\", \"How MYD88 selects transcriptional vs metabolic outputs unresolved\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How the wild-type vs L265P Myddosome achieves distinct conformational states and selects among the diverse downstream programs (NF-\\u03baB, STAT3, Wnt, ARF6, mRNA stabilization, itaconate) in a cell-type-specific manner remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No high-resolution structure of the mutant Myddosome\", \"Rules governing output selection across cell types undefined\", \"Quantitative contribution of vesicular MYD88 transfer in vivo unknown\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0060090\", \"supporting_discovery_ids\": [0, 7, 12, 25]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [5, 8, 15]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [0, 7, 11]},\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [7, 8]},\n      {\"term_id\": \"GO:0005739\", \"supporting_discovery_ids\": [6]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [0, 1, 2, 4, 11, 17]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [0, 5, 15]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [11, 14, 19, 23]},\n      {\"term_id\": \"R-HSA-392499\", \"supporting_discovery_ids\": [17, 21, 23]}\n    ],\n    \"complexes\": [\n      \"Myddosome\"\n    ],\n    \"partners\": [\n      \"IRAK4\",\n      \"IRAK1\",\n      \"TRAF6\",\n      \"IFNGR1\",\n      \"PRKCE\",\n      \"PTK2B\",\n      \"SPOP\",\n      \"RNF138\"\n    ],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":9,"faith_total":9,"faith_pct":100.0}}